
SINOVAC科兴

SINOVAC BIOTECH LTD.

Corporate Social Responsibility Report

2021



About this Report

Time Span

This report is an annual report with a time span from January 1, 2021 to December 31, 2021. To enhance the completeness of the report, some data cited hereof are beyond the foregoing range.

Organizational Scope

This report covers Sinovac Biotech Ltd. (Sinovac) and its subsidiaries including Sinovac Biotech Co., Ltd. (Sinovac Beijing), Sinovac Life Sciences Co., Ltd. (Sinovac LS) and Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). For convenience of expression, "Sinovac" and "the Company" are used hereunder to refer to the subject of this report.

Reference Standards

Sustainable Development Goals (SDGs)

Ten Principles of the United Nations Global Compact

Global Reporting Initiative (GRI): Sustainability Reporting Standards

Guidelines on Corporate Social Responsibility Reporting for Chinese Enterprises (CASS-CSR 4.0)

Information Source

The information and data in this report mainly come from the internal data collection systems, statistical reports and public data of the Company as well as information released by authoritative media. The right to the final interpretation of all data herein belongs to Sinovac.

Approach to Access the Report

You are welcomed to download the electronic report and obtain more information on our social responsibility via our official website (http://www.sinovac.com.cn/index.php?lang=en/).

Foreword

All the members of Sinovac share a viewpoint: to have a long-term commitment to a tough yet correct task from the perspective of the long-term development of human society. Currently, it is incumbent social responsibility of Sinovac to provide high-quality and affordable vaccines and control diseases, which are enduring (rather than short-term) and far-reaching. In retrospect, members of Sinovac have always believed that vaccines play a significant role in safeguarding the health of human society. In spite of diversified difficulties, setbacks and challenges it has experienced, Sinovac remains firmly committed to its cause that benefits the nation and the people.

Upon the outbreak of the COVID-19 pandemic at the beginning of 2020, human beings were ravaged by an unprecedented epidemic in history. Then, members of Sinovac stood up with determination and sped up efforts to race against epidemic by advancing vaccine R&D, clinical study and large-scale production without hesitation, only desiring to launch vaccines for safeguarding human health regardless of the gains and losses. It was the responsibility to control the epidemic that underpins this decision. By the end of 2021, more than 2.5 billion doses of CoronaVac®, the COVID-19 inactivated vaccine developed by Sinovac, have been supplied to over 50 countries and regions including China, and more than 2 billion doses have been vaccinated, protecting hundreds of millions of people worldwide.

It was in 2002, 20 years ago, that the Inactivated Hepatitis A Vaccine, Healive®, developed by Sinovac was launched on the market. As the first inactivated hepatitis A vaccine independently developed by China, it marks the end of China's dependence on the imported inactivated hepatitis A vaccines. Since then, Sinovac began to command the attention of the public. And it had been 17 years upon Sinovac finished the report Isolation and Propogation of a Strain HAV in Human Diploid Cell line (2BS) in 1985. After obtaining the World Health Organization Prequalification (WHO-PQ) in 2017, Healive® now has been sold to more than 20 countries worldwide with over 100 million doses vaccinated worldwide. With the improvement of social, economic and health conditions in China and the large-scale vaccination of the inactivated Hepatitis A vaccine, the incidence rate of hepatitis A has declined from previous 60-200/100,000 to 1/100,000 now, turning China into a low-endemic area of hepatitis A. People no longer worry about the influence of hepatitis A on their daily life. Such health value is beyond any economic measurement.

Sinovac has always prioritized the demands of the country, the society and the public, and taken the scientific innovation as the driving force for progress. From conducting successful R&D of the first inactivated hepatitis A vaccine, to experiencing the outbreak of various epidemics in and outside China including SARS, avian influenza, influenza A (H1N1) and COVID-19 pandemic, and then to preventing conventional diseases like flu, pneumonia, polio and varicella, Sinovac become more and more experienced. At present, the COVID-19 pandemic is not over yet, and Sinovac is still challenged by continued virus mutations, pandemic outbreaks around the world, and the masses' concern over the reliability and validity of vaccines. In this connection, further efforts have been made by Sinovac to carry out the real-world study of inactivated COVID-19 vaccines and relevant research on variant-updated COVID-19 vaccines, update epidemic prevention and control technologies, strengthen the health science popularization among the masses, and provide scientific basis and technological means to the country for adjustment of the epidemic prevention and control strategies.

The essence of health is "prioritizing prevention over treatment". For Sinovac, we unceasingly spot prominent problems in the life science and health fields, resolve those problems by virtue of continuous scientific research, and create as many high-quality and affordable products and services as possible to contribute to the society in the way of large-scale industrialization. These are not only the responsibility of Sinovac, but also the driving force and pursuit of Sinovac that lead to its perpetual development.

TABLE OF CONTENTS

Foreword 02

Social Responsibility Strategy and Management 13

Corporate Social Responsibility Strategy and Management 13
Communication with Stakeholders 15
Analysis on Substantive Issues 16

Excellent Governance to Enhance Sustainable Development 33

Compliance and Risk Control 35
Integrity Management 37
Responsible Supply Chain 39

Communion and Co-Construction Create Shared Value 49

Promote the Sound Development of the Industry 51
Proactively Carry out International Cooperation 53

Heartwarming Workplace Grow with Employees 69

Protection of Employees' Rights and Interests 71
Diversity of Employees and Equality of Opportunities 72
Occupational Health and Safety of Employees 72
Employee Growth and Development 74
Care for Employees 77

01 About this Report

05 About Sinovac

05 Corporate Profile
07 History
11 Main Products

17 Contribution to the Realization of 2030 Sustainable Development Goals of the United Nations

17 SDGs Map of Sinovac
19 Drive the "ANTI COVID-19 ACTION" to fight against the COVID-19 pandemic
25 Benefit the World and Contribute to Fight against the COVID-19 Pandemic Worldwide through Sinovac's Vaccines
33 Remain dedicated to the R&D and supply of vaccines for 20 years

41 Continuous Innovation for Better Health

43 R&D and Innovation
44 Vaccine Quality and Supply
47 Customer Service

59 Green Development Build Beautiful Home

61 Environmental Management Framework
63 Make Aggressive Efforts for Energy Conservation and Emission Reduction
63 Fully Carry out Cleaner Production
67 Water Resource Management
68 Green Logistics and Warehousing

Benefit the Society Achieve Common Prosperity 79

Deliver Health and Wellbeing by Fulfilling Public Responsibility 81
Safeguard the Public Health through Health Science Popularization 82

2021 Key Performance Sheet 87

85 Embrace the Future

89 Indicator Index (GRI)



About Sinovac

Corporate Profile

As a biological high-tech enterprise headquartered in Beijing and listed in NASDAQ Global Select Market (NQGS: SVA), Sinovac Biotech Ltd. now controls five companies, including Sinovac Biotech Co., Ltd., Sinovac Life Sciences Co., Ltd., Sinovac (Dalian) Vaccine Technology Co., Ltd., Sinovac (Singapore) Ltd. and Sinovac Biomed Co., Ltd. through its wholly-owned subsidiary Sinovac Biotech (Hong Kong) Ltd., and four industrial bases in Haidian, Changping and Daxing districts of Beijing, and Liaoning of Dalian respectively.

With its mission of "Supply Vaccines to Eliminate Human Diseases", Sinovac focuses on the research, development, production and sales of human vaccines and relevant products to provide services for disease prevention and control. Over the past 20 years, the Company has always been committed to meeting the health needs of the country and the people, forging ahead and constantly innovating. It has been fighting at the forefront of vaccine research and development when national major epidemics broke out and has dedicated to the prevention and control of of these epidemics, such as hepatitis A, SARS, avian influenza, H1N1 influenza, hand, foot and mouth disease (HFMD) and COVID-19, and have sustainably developed high-quality vaccines. At present, Sinovac's overseas business covers more than 80 countries and regions, and promotes overseas R&D cooperation and production base construction in Brazil, Chile, Colombia, Egypt, Indonesia and other countries.

Corporate Culture

Mission — Supply Vaccines to Eliminate Human Diseases

Conception — Protecting Lives, Delivering Health

Key Performance (By the end of 2021)

Successively undertaken national and local scientific research projects
≈ 60

Obtained national science and technology awards
4

Provincial science and technology progress awards
5

Published SCI papers
>70

Applied patents
>130

Authorized patents
80

Major Honors and Awards

Jan. 2021

Sinovac LS
the "ANTI COVID-19 ACTION" task force
was award by Beijing Committee of the Communist Youth League
"Youth Commando of Beijing Municipality"

Apr. 2021

Sinovac Dalian
was awarded by the People's Government of Liaoning Province
Advanced Collective of Liaoning Province in the Fight Against COVID-19

Dec. 2021

Sinovac LS
was awarded by the Ministry of Science and Technology of the People's Republic of China
Advanced Collective in the National Science and Technology System in the Fight Against COVID-19

Apr. 2021

Sinovac LS
the "ANTI COVID-19 ACTION" task force
was awarded by the Central Committee of the Communist Youth League and All-China Federation of Youth
the 25th China Youth May Fourth Medal Collective

May. 2021


Sinovac LS
the "ANTI COVID-19 ACTION" task force
was awarded by BJWMB (www.bjwmb.gov.cn) of the Publicity Department of the Communist party of China (CPC) Beijing Municipal Committee
2021 Monthly Model Team of Beijing Model

History

1982

Mr. Weidong Yin, the Founder of Sinovac, conducted research in the epidemic area of hepatitis A.

1985





He successfully isolated the TZ84 strain of the hepatitis A virus.

1987



China's first Hepatitis A enzyme-linked diagnostic reagent was developed.

1996



Mr. Yin cooperated with the National Institute for the Control of Pharmaceutical and Biological Products to initiate the development of inactivated hepatitis A vaccines.

2001




Sinovac Biotech Co., Ltd. was incorporated in Beijing.

2002



China's first Inactivated Hepatitis A Vaccine, Healive®, was commercially launched.

2003



Sinovac initiated the research and development of an inactivated SARS vaccine.

2004



Sinovac initiated study on the pandemic influenza vaccine against human infection with highly pathogenic avian influenza (H5N1);

Sinovac unblinded the world's first SARS inactivated vaccine phase I clinical trial results.

2005

Sinovac commercially launched China's first and the world's second Hepatitis A & Hepatitis B Combined Vaccine, Bilive®.

2006




Sinovac commercially launched Influenza Vaccine (Split Virion), Anflu®.

History

2007

Sinovac ranked the first enterprise in developing countries that joined the Influenza Vaccine Supply International Task Force (IVS) affiliated with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

2008



China's first Pandemic Influenza Vaccine (Inactivated, Adjuvanted), PanFlu®, was approved to be produced for government stockpiling.

2009

The world's first H1N1 Influenza A Inactivated Vaccine (Split Virion), Panfu.1®, was approved for production and mass vaccination started;

Sinovac stepped into the international market, with its Healive® vaccine exported to Mongolia and its Anflu® vaccine exported to the Philippines;

Sinovac Life Sciences Co., Ltd. was incorporated.



2010

Sinovac (Dalian) Vaccine Technology Co., Ltd. was incorporated.

2012

Sinovac commercially launched attenuated Mumps Vaccine.

2016



Sinovac commercially launched the world's first class I drug for preventative biological products - Enterovirus Type 71 Inactivated Vaccine (Vero Cell), Inlive®.

2017

Sinovac's Inactivated Hepatitis A Vaccine, Healive®, passed the pre-qualification assessment by the WHO, making it the only Hepatitis A vaccine in Asia that reached this milestone.



2020



Initiated the "ANTI-COVID-19 ACTION" program for the R&D of COVID-19 vaccine, CoronaVac®, which was one of the first vaccines against COVID-19 in China to be approved for emergency use;

Sinovac commercially launched the attenuated Live Varicella Vaccine;

Sinovac commercially launched the Inactivated Quadrivalent Influenza Vaccine (Split Virion);

Sinovac commercially launched the 23-valent Pneumococcal Polysaccharide Vaccine.

2021

Sinovac's Inactivated COVID-19 Vaccine, CoronaVac®, was listed in WHO Emergency Use Listing (EUL);

CoronaVac®, the COVID-19 inactivated vaccine developed by Sinovac, was granted conditional marketing or emergency use authorization in dozens of countries, including China, Chile, Turkey, Brazil and Indonesia;

The Inactivated Poliomyelitis Vaccine (Vero Cell), Sabin Strains was approved for marketing.



Main Products

Sinovac's main products includes COVID-19 Vaccine (Vero Cell), Inactivated (CoronaVac®); Enterovirus Type 71 Vaccine (Vero Cell), Inactivated (Inlive®); Hepatitis A Vaccine (Human Diploid Cell), Inactivated (Healive®); Hepatitis A & Hepatitis B Combined Vaccine - Bilive®; Influenza Vaccine (Split Virion), Inactivated, Trivalent (Anflu®); Influenza Vaccine (Split Virion), Inactivated, Quadrivalent; 23-valent Pneumococcal Polysaccharide Vaccine; Varicella Vaccine, Live; Mumps Vaccine, Live; and Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains. Furthermore, Sinovac has successively developed the world's first SARS Vaccine, Inactivated (phase I clinical trial completed), China's first Pandemic Influenza Vaccine, Inactivated (H5N1) (Panflu®), and the world's first H1N1 Influenza A Vaccine (Split Virion), Inactivated (Panfu.1®), thus contributing to the prevention and control of diseases in China and even the world.



COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®

- Over 300 studies around the world have proven that CoronaVac® is safe and effective in people aged 6 months and above and special populations.
- Real-world studies show that CoronaVac® is effective against multiple COVID-19 variants.
- By the end of 2021, 59 countries, regions and international organizations approve for use in adults.
- By the end of 2021, the global supply of CoronaVac® is over 2.5 billion doses. It was included in the WHO Emergency Use Listing (EUL) and recognized by many countries, enabling easy access to more countries.

Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®

- Suitable for a wide range of ages: effective protection against the Enterovirus 71 (EV71) for children aged 6-71 months can be provided.
- Fast effect-taking: the antibody positive rate will reach 89.2% within 10 days after 1 dose of vaccination, which quickly plays a protective role.
- Long-term protection: after completing the vaccination course (2 doses), the vaccinated people can be protected for at least 5 years, protecting children during the preschool susceptible period.
- There is abundant research evidence for simultaneous vaccination: EV71 vaccine can be vaccinated at the same time as hepatitis B, meningitis, measles, Japanese encephalitis vaccine, etc.
- No additional stabilizers are added and it is valid for up to 3 years.



Influenza Vaccines

- Sinovac has the most comprehensive product line of influenza vaccines in China.
- Anflu®, launched in 2006, is China's first preservative-free trivalent influenza vaccine.
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, was launched in 2020 and developed independently by Sinovac.
  - It covers wide coverage of serums and provides more comprehensive protection.
  - It adopts 5 technical routes for purification to maintain the integrity of the antigen and ensure better immunogenicity.
  - Innovative chromatography process is adopted to efficiently remove impurities. No preservatives are added, and more secure inoculation is achieved.
- PanFlu®, China's first Pandemic Influenza Vaccine, Inactivated (H5N1), was approved to be produced for government stockpiling in 2018.
- PanFlu.1®, the world's first H1N1 Influenza A Vaccine (Split Virion), Inactivated was approved for production and started mass vaccination.
- The project "Key Technologies for Evaluation of Pandemic Influenza Vaccines and diagnostic reagents: Innovation and Application" won the first prize of the 2010 Science and Technology Award of Chinese Pharmaceutical Association, the first prize of the 2010 Beijing Science and Technology Progress Award, and the second prize of the 2011 National Science and Technology Progress Award.



Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive®

- It is the only hepatitis A vaccine in China that was pre-qualified by WHO, exported to more than 20 countries around the world.
- It is the most used and most evidence-based inactivated hepatitis A vaccine in China.
- No preservatives are added. It is the inactivated hepatitis A vaccine with the longest validity period (3.5 years) in the world.
- It can be vaccinated at 12 months of age, taking effects rapidly, and be used for emergency vaccination.
- It provides long-lasting immune protection for 30 years, featuring good safety.



23-valent Pneumococcal Polysaccharide Vaccine

- It covers wide coverage of serums and provides more comprehensive protection.
- It adopts 5 technical routes for purification to maintain the integrity of the antigen and ensure better immunogenicity.
- Innovative chromatography process is adopted to efficiently remove impurities. No preservatives are added, and more secure inoculation is achieved.



Varicella Vaccine, Live

- The protection rate of varicella confirmed cases is 87.1%.
- New technology: new cell line, clear traceability, and high safety and stability.



Mumps Vaccine, live

- The production process is leading in China and no antibiotics are added in the whole process.
- The antibody positive rate is as high as 88.9% after 1 dose of booster shot.



Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

- Strict quality control standards: no preservatives and antibiotics are added.
- Good safety: phase III clinical studies show that the safety is good, and the related adverse events are all grades 1 and 2.
- High immunogenicity: After the basic immunization and booster immunization, the seroconversion rate was more than 90%. After the basic immunization, the seroconversion rate of type I and II was better than that of the control group.

Corporate Social Responsibility Strategy and Management

Driven by its mission of "Supply Vaccines to Eliminate Human Diseases", Sinovac remains committed to the R&D, manufacturing and sales of human vaccines and relevant products, and has unceasingly provided safe and effective high-quality vaccines and complete and considerate services to the society and the public. For Sinovac, it is corporate social responsibility that drives the Company to achieve its sustainable development. In this connection, Sinovac always attaches great significance to its social responsibility, and works to fulfill its social responsibility. Specifically, it has deliverd health concepts and products to numerous people, satisfied the global unmet needs for disease prevention and control, facilitated the development of public health undertaking with concrete actions, and cooperated with others from all sectors to jointly build a healthier world.

Corporate Social Responsibility Strategy of Sinovac

Mission: Supply Vaccines to Eliminate Human Diseases

Compliance Management	Win-win Value	High-quality Products	Staff Care	Green Operation	Public Welfare
Continuously improve compliance management, intensify our efforts in risk prevention and control, and combating corruption and upholding integrity and other major compliance work, implement the basic principle of "holding the bottom line of systems and building the defensive line of compliance", and facilitate the sound development of the Company.	Proactively organize and participate in industry exchanges, and remain committed to building the mutually beneficial industrial ecology, and promote the sound development of the industry.	Stick to R&D and innovation-oriented development to provide users with high-quality and affordable vaccines, and contribute to the global health industry.	Build a vital and inclusive working environment to empower employees to carry out their roles, and encourage them to embrace sustainable development together with the Company.	Unswervingly implement the green development strategy, facilitate carbon emission reduction and carbon neutrality, and strike a balance between economic development and environmental protection.	Benefit the society with the fruits of the development of the Company, take its advantages to support fundamental research and scientific and technological innovation in the life science field, and to encourage the community-based public health and medical services.

The fulfillment of corporate social responsibility is underpinned by scientific and effective governance. In pursuit of the unified understanding and effective implementation of corporate social responsibility, Sinovac has established an integrated governance framework of corporate social responsibility to integrate social responsibility with its development strategies, daily management, business operation and other aspects, promoting the sound and sustainable development of the Company.

Management Committee of Corporate Social Responsibility	• Supervise the formulation of visions and strategies pertaining to corporate social responsibility Supervise the implementation of visions and strategies pertaining to corporate social responsibility Supervise the expenditures on the fulfillment of corporate social responsibility • Supervise the information disclosure policies • Other duties
Task Force of Corporate Social Responsibility	• Assist the Management Committee of Corporate Social Responsibility in formulating the visions and strategies pertaining to corporate social responsibility, and in setting the management objectives of corporate social responsibility • Regularly report the management and performance of corporate social responsibility to the Management Committee of Corporate Social Responsibility, and deliver corporate social responsibility decisions to all departments • Organize corporate social responsibility stakeholders engage in and develop a communication plan of stakeholders • Collect and disclose the implementation progress as well as various indicators of the corporate social responsibility • Facilitate the implementation of projects of corporate social responsibility, and enable all departments to fulfill corporate social responsibility
Relevant Functional Departments of Corporate Social Responsibility	• Jointly take charge of the implementation of relevant policies and objectives




Communication with Stakeholders

Proactive communication with stakeholders is vital for Sinovac to achieve the sustainable development. Throughout its development process, Sinovac lays emphasis on the communication with major stakeholders including government, shareholders, customers, employees, suppliers, partners, the masses and communities, and has made ongoing efforts to improve its communication mechanism. By means of timely disclosure of the work information and activity details about corporate social responsibility at official website, WeChat and mainstream media websites, and participation in industry forums and meetings, Sinovac promotes its corporate philosophy and duty performance dynamics, unceasingly expands the communication coverage, and actively responds to the expectations and appeals of stakeholders for common development.

Stakeholder	Issue	Manner of Response
Government and regulatory institutions	• Working together to face the challenges during the COVID-19 pandemic • Compliance management • Product safety and quality • Product innovation and R&D • Leading the sound development of the industry	• Proactively responding to anti-epidemic call and ensuring vaccine supply • Operating in good faith and paying taxes in accordance with the law • Improving the product quality management system • Performing scientific research and innovation • Participating in government projects and industry collaboration
Shareholders and potential investors	• Sustainable investment value • Compliance management and standard governance • Public and transparent corporate information	• Safeguarding the rights and interests of shareholders • Creating value for shareholders by improving the business performance of the Company • Building a sound communication mechanism for investors • Regularly releasing financial information and company announcements
Customers	• Safe and reliable products • Protection of customers' rights, interests and privacy • Product accessibility • Responsible marketing	• Satisfying the demand for disease prevention and control • Optimizing the quality management system • Making vaccines accessible to the public • Upgrading the after-sale service network • Ensuring the information security of the customers • Carrying out science popularization for disease prevention • Developing differentiated vaccines to cater to the demands of different population groups
Employees	• Protection of employees' legitimate rights and interests • Employee health and safety • Emphasis on career development and training • Care for daily life of employees	• Offering competitive salary and welfare • Launching education and training programs • Building career development channels • Organizing diversified staff care activities
Suppliers and partners	• Fair and impartial cooperation • Sincere and mutual-benefit supply • Joint contribution to the development of the industry	• Observing laws and disciplines • Carrying out communication and cooperation for mutual benefit and win-win results • Reinforcing the supply chain management and perfecting the procurement system • Carrying out communication and cooperation in and outside China
General public and communities	• Assistance to groups with difficulties • Getting involved in social welfare service • Creating employment opportunities	• Carrying out diversified charitable and supporting activities • Popularizing health knowledge • Providing job positions

Analysis on Substantive Issues

To make the report more well-targeted, substantive and complete, and to understand the significance of different social responsibility issues to stakeholders and corporate development, Sinovac, by analyzing domestic and overseas social responsibility standards as well as national and local policies, after fully considering the industry characteristics, has concluded and sorted out substantive issues from two dimensions, namely, significance to the sustainable development of the Company and significance to stakeholders, and offered an effective reference for enhancing the management of future sustainable development while performing targeted disclosure.



Contribution to the Realization of 2030 Sustainable Development Goals* of the United Nations

The full realization of the Sustainable Development Goals of the United Nations (SDGs) is pursued by all human beings. In 2016, with the release of the *China's National Plan on Implementation of the 2030 Agenda for Sustainable Development*, a guide for action was provided for all sectors in China to implement the sustainable development agenda. In 2021, confronted with the demands for epidemic prevention and control, high-quality development and solid production and operation, Sinovac has firmly adhered to its mission of "Supply Vaccines to Eliminate Human Diseases" to ensure the R&D, manufacturing and supply of vaccines, and the health and well-being for all.

SDGs Map of Sinovac

SDGs	Measures of Sinovac
Goal 1: No poverty End poverty in all its forms everywhere.	Sinovac leverages its technical and industrial strength in the vaccine R&D and manufacturing fields to help people in underdeveloped countries and regions enhance their ability to resist diseases and reduce the poverty caused by illness. In the meantime, it carries out diversified public benefit activities to narrow the gap between the rich and the poor between these countries and regions.
Goal 3: Good health and well-being Ensure healthy lives and promote well-being for all at all ages.	In pursuit of the mission of "Supply Vaccines to Eliminate Human Diseases", Sinovac has made ongoing efforts to develop new vaccines and facilitate immunization, further increase the inoculation rate of vaccines and lower the incidence rate, and safeguard the health of human beings with vaccines.
Goal 4: Quality education Ensure inclusive and equitable quality education and promote lifelong learning opportunity for all.	Sinovac not only has trained talents for the Company by virtue of its R&D and platform advantages, but also has cooperated with a number of universities, research institutes and scientific research institutions at home and abroad to continuously train industry talents.
Goal 8: Decent work and economy growth Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all.	Sinovac provides its employees with equal, safe and decent work, supporting them with equitable salary, better working environment, upgraded welfare guarantees and more promising personal development prospect. With its R&D strength, Sinovac, while creating employment opportunities, fuels the development of upstream enterprises in the industry chain, and continuously encourages the economic growth of the industry.
Goal 9: Industry, innovation and infrastructure Enhance scientific research and technological capacity, promote inclusive and sustainable industrialization and foster innovation.	As a result of its due attention paid to the R&D and innovation, the Company, since it was incorporated, has taken the lead in developing multiple vaccines nationwide and even worldwide, obtained national invention patents by developing diversified core technologies, published numerous research achievements on domestically and internationally authoritative academic journals, and encouraged innovation to contribute to the disease prevention and control.
Goal 10: Reduced inequalities Reduce inequality within and among countries.	Relying on its own product advantages, Sinovac has always been committed to providing fair and accessible vaccines and health products to the people around the world. After the outbreak of the COVID-19 pandemic, Sinovac actively supported the "COVID-19 Vaccines Global Access (COVAX)", by providing vaccines to overseas regions, carrying out technical cooperation and building local factories, etc., to widely supply vaccines around the world and promote the equitable distribution of vaccines on a global scale to facilitate reducing differences between countries and regions.
Goal 12: Responsible consumption and production Ensure sustainable consumption and production patterns.	Sinovac strictly controls over production, and encourages the effective utilization of resources by virtue of intelligent production. In the meantime, it imposes strict management on all links of the value chain for the purpose of ensuring product quality and safeguarding customers' rights and interests.
Goal 17: Partnerships for the Goals Strengthen the means of implemention and revitalize the global partnerships for sustainable development.	Sinovac continuously renders assistance to third world countries in multiple channels to promote local vaccination and reduce the incidence rate of diseases. In the meantime, it unceasingly drives the international cooperation and exchange for vaccine R&D and inoculation, jointly driven the realization of SDGs.

* Sustainable Development Goals, with abbreviation as SDGs, refer to a collection of 17 global development goals formulated by the United Nations to continuously direct the global development from 2015 to 2030 upon expiry of 2000-2015 Millennium Development Goals (MDGs).



Drive the "ANTI COVID-19 ACTION" to Fight against the COVID-19 Pandemic

Whenever an epidemic broke out since our inception, members of Sinovac always stand at the front line of vaccine R&D without hesitation, and make unremitting efforts to ensure the national public health security and protect the well-being of the people.

Jan. 28, 2020

Sinovac set up the task force to launch the COVID-19 vaccine research project named "ANTI COVID-19 ACTION".



Mar. 3, 2020

The first batch of rhesus monkeys was vaccinated against COVID-19 and subjected to challenge tests, which proved that Sinovac's COVID-19 Vaccine (Vero Cell), inactivated can effectively prevent SARS-CoV-2.



Mar. 29, 2020

Sinovac started to construct the plants for COVID-19 vaccines.



Apr. 13, 2020

CoronaVac®, the COVID-19 inactivated vaccine developed by Sinovac, was approved by the National Medical Products Administration for clinical research.



Apr. 16, 2020

The phase I clinical research of CoronaVac® was officially launched in Suining County, Xuzhou, Jiangsu Province.



Jun. 24, 2020

CoronaVac®, the COVID-19 inactivated vaccine developed by Sinovac, was approved for emergency use (trial).




Jun. 30, 2020

Phase I plant construction was completed in 99 days, with an annual production capacity of 300 million doses.



Jul. 3, 2020

phase III clinical research of CoronaVac® was approved by the National Health Surveillance Agency (ANVISA) in Brazil. On Jul. 21, the research was officially launched, marking the beginning of the oversea scientific research.



Feb. 5, 2021

CoronaVac® was granted conditional marketing authorization in China by the National Medical Products Administration.



Apr. 1, 2021

Sinovac's bulk workshop (phase III) for COVID-19 vaccine was constructed and put into production, and its annual production capacity of CoronaVac® exceeded 2 billion doses.



Jun. 1, 2021

WHO listed CoronaVac®, Sinovac's COVID-19 vaccine, for emergency use.



Jun. 28, 2021

More than 1 billion doses of Sinovac's COVID-19 vaccine had been supplied worldwide.

Jul. 22, 2021

Beijing took the lead in launching Sinovac's COVID-19 vaccine for emergency use (trial).



At the end of Dec. 2020

The results of interim analysis of the phase III clinical trial of CoronaVac®, the COVID-19 inactivated vaccine developed by Sinovac, were successively released.



Oct. 5, 2021

More than 2 billion doses of Sinovac's COVID-19 vaccine had been supplied worldwide.



Dec. 31, 2021

More than 2.5 billion doses of Sinovac's COVID-19 vaccine had been supplied worldwide.



Speed is Precious in War

At the beginning of 2020, the COVID-19 picture remained uncertain. Sinovac, adhering to the original aspiration and mission of "Supply Vaccines to Eliminate Human Diseases", and relying on its abundant experience in combating infectious diseases, studied and predicted the development trend of COVID-19 without hesitation, and made a decision resolutely. On January 28, 2020, it launched the COVID-19 vaccine research and development project named "ANTI COVID-19 ACTION". Two days later, the first scientific research team of Sinovac was stationed in the biosafety Level 3 laboratory (BSL-3 Lab) of Zhejiang Provincial Center for Disease Control and Prevention. From the entrance into the BSL-3 Lab to the initiation of fundamental research, relevant government departments coordinated in terms of the BSL-3 Lab, transfer of COVID-19 virus strains, collection of serum specimen, and provision of experimental animals.

Upon initiation of the project, all members of Sinovac raced against time to carry out vaccine R&D, advanced vaccine research and registration procedure synchronously, changing the development patterns from "in series" to "in parallel", and with no reduction in procedures and standards, facilitated vaccine development in full speed on the premise of respecting scientific laws and ensuring safety and effectiveness. Directed by the overall objective formulated by the government and thanks to the coordination of multiple government departments, Sinovac gradually presented its vaccine R&D achievements: On February 23, 2020, the preliminary evidence was obtained to prove that the inactivated and purified virus can stimulate the animals to generate neutralizing antibodies and there is an obvious dose-effect relationship between the stimulus and the magnitude of the response of the animals, as well as the feasibility of developing an inactivated COVID-19 vaccine; on April 13, the scientific research team of Sinovac completed the pre-clinical research of the inactivated COVID-19 vaccine (77 days in total), and obtained the clinical approval.

Secure Mass Production

Due to the extremely strict conditions required by vaccine manufacturing, it usually takes several years from R&D to the construction of high-standard factories. In response to the rampant COVID-19 pandemic, however, Sinovac laid out the construction of the plants in advance at all costs and risks, and advancing that together with vaccine R&D, in a bid to ensure the immediate manufacturing of vaccines upon successful R&D. When the COVID-19 inactivated vaccine developed by Sinovac was at the laboratory stage by the end of March 2020, the phase I plants of high-level biosafety for COVID-19 vaccine manufacturing had had its construction initiated with a designed production capacity of 300 million doses. Due to the coordination and support of the government at all levels, adequate supply ensured by equipment suppliers and tireless work by the construction unit, Sinovac succeeded in achieving the "ANTI COVID-19 Speed" of constructing the COVID-19 inactivated vaccine plants in 99 days. In June 2020, the COVID-19 inactivated vaccine developed by Sinovac was approved by the government for emergency use (trial); on February 5, 2021, CoronaVac® was granted conditional marketing authorization in China by the National Medical Products Administration in accordance with the Chinese law; on June 1, 2021, WHO officially listed CoronaVac®, Sinovac's COVID-19 vaccine for emergency use due to its excellent characteristics.

With the changing COVID-19 picture and the international supply-and-demand pattern, there was great uncertainty confronting the domestic and international vaccine demands, and it was a huge challenge in how to accurately grasp such uncertainty. In this context, Sinovac put the national and social demand for vaccines in the first place, and made aggressive efforts to drive the vaccine production capacity subject to the design principle of excessive production capacity regardless of its investment risks. Subsequently, phase II and III plants of Sinovac were constructed and put into production prior to April 1, 2021, realizing an annual production capacity of 2 billion doses and further ensuring the vaccine supply in and outside China. Meanwhile, Sinovac took the lead in building the biosafety management system for higher biological risks plants in China, holding fast to the defense line of biosafety throughout the production of inactivated COVID-19 vaccine, and prioritized the prevention of risks, thus ensuring zero accident all throughout the year of production.

By the end of 2021, more than 2.5 billion doses of CoronaVac® had been supplied worldwide, and more than 2 billion doses had been vaccinated globally. One out of every four doses of the COVID-19 vaccine in the world is made by Sinovac.

Characteristics of Sinovac's Inactivated COVID-19 Vaccine

High Safety


Low occurrence rate of adverse reaction, thus making vaccination more reassuring and applicable for massive vaccination

Excellent Stability

Shelf life of 24 months at the temperature of 2-8°C , thus contributing to the global accessibility

Extensive Verification

CoronaVac® has been demonstrated to be effective in preventing hospitalizations, severe illness, and death according to the real-world studies in many countries





At the end of March 2020, Sinovac initiated the construction of the plants for COVID-19 vaccines resolutely for the sole purpose of racing against the time in fighting the COVID-19 pandemic.

Impose Strict Control over Quality

To ensure the safety and efficacy thereof, "ANTI COVID-19 ACTION" developed by Sinovac is directed by international standards, in line with the goal of attaining the highest quality, and has the prudent attitude maintained throughout R&D. Amid all the batches of COVID-19 vaccines manufactured by Sinovac, the quality of vaccines in each batch conforms to the registration standards and the internal control quality standards, and the lot release testing is 100% qualified, resulting in the stable product quality and controllable risks and ensuring the safety and effectiveness of Sinovac's vaccines. Upon the initiation of "ANTI COVID-19 ACTION", besides, the production quality management system of Sinovac has successively passed the Good Manufacturing Practice (GMP) inspections of and been approved by the drug regulatory authorities of multiple countries and international organizations, including China, Brazil, Indonesia, Turkey, Chile and WHO.

Research & Development Roadmap

Pre-clinical Research

- Effectiveness: immunogenicity test: mice and rats
- Protective evaluation: cross-protection test of rhesus monkeys
- Safety: Acute toxicity test: rats Sensitivity test: guinea pigs
  Chronic toxicity test (repeated-dose toxicity test): machins and rats
  Reproductive/ developmental toxicity test: rats

Phase I/II Clinical Trial

- Safety
- Tolerance
- Immunogenicity
- Immune persistence

Phase III Clinical Trial

- Safety
- Efficacy
- Immunogenicity
- Immune persistence
- Cross neutralization effect

Phase IV Clinical Trial

- Safety
- Combined immunization
- Efficacy / effect
- Special population
- Immune persistence

Results of preclinical research on the first COVID-19 vaccine



Results of phase I/II clinical research on CoronaVac® in adult group



Results of phase I /II clinical research on CoronaVac® in elderly group



Results of phase I/II clinical research on CoronaVac® in minor group aged 3-17



Interim results of phase III clinical research on CoronaVac® in Turkey



Research Results at Different Stages

Upgrade the Industry Chain of Vaccine Development and Production

Sinovac has influenced the development pattern of the upstream industry chain of COVID-19 vaccines while ensuring the output and quality thereof. First, the production of inactivated COVID-19 vaccines in 2021 has directly contributed to the substantial growth of upstream raw material supplier's production value and performance. For instance, the trade volume of the top 44 suppliers of Sinovac LS in 2021 increased by an average of 46 times compared with that in 2020, fundamentally covering all suppliers in all the links of the industry chain of COVID-19 vaccine production, including bovine serum for bulk cultivation, disposable stirring bags and storage bags, vials and printing and packaging materials, etc., thus fueling the rapid development of upstream raw material suppliers of COVID-19 vaccines. In addition, Sinovac, throughout the production of vaccines, performed experimental verification and inspection of key materials provided by suppliers for multiple times. If any material provided by suppliers was found to be unqualified during the inspection process, Sinovac would promptly return the materials and offer timely feedback to the suppliers, communicate the process throughout the use with the suppliers, jointly tap the approach for optimization, and continuously purchase materials from the suppliers upon the quality was improved, which enables suppliers to improve quality while ensuring material supply. Due to the continuous expansion of the COVID-19 vaccine production scale in China, the unprecedented development speed of the Chinese pharmaceutical industry, and the huge future market size, a growing number of upstream international raw material suppliers have stepped up their pace of constructing plants in China for production, which further leads to a more stable vaccine supply chain in China.

Acknowledgement Received by Sinovac from Multiple Governments Worldwide

In pursuit of its mission of "Supply Vaccines to Eliminate Human Diseases", Sinovac always gives priority to the national demands and the health needs of the public, for which it manages to initiate the R&D of COVID-19 vaccines in the first place, and repay the state and the society through high-quality vaccines. In the context that the COVID-19 pandemic is still raging on a global scale, Sinovac LS renders vigorous support to the R&D, production and prevalence of COVID-19 vaccines, facilitates the global epidemic prevention and control, and applies vaccines to benefit the globe and safeguard the health of human beings, thus it is highly recognized at home and abroad, and overwhelmed by acknowledgement from governments in and outside China.



Benefit the World and Facilitate the Fight against the COVID-19 Pandemic Worldwide through Sinovac's Vaccines

As a COVID-19 vaccine manufacturing enterprise, Sinovac proactively responds to the call of the country, unswervingly takes the lead in international anti-pendemic cooperation, unceasingly enhances the safety and accessibility of vaccines, and cooperates with all parties to jointly guard the life and health of the people on a global scale.

Jointly Build the Human Community with a Shared Future

Following the outbreak of the COVID-19 pandemic, Sinovac has made aggressive efforts to enhance the international cooperation in fighting COVID-19, promoting the R&D, manufacturing and distribution of vaccines as global public products by arranging the domestic and international linkage pattern.

Carry out global cooperative study and manufacturing to lay a solid foundation for the global supply of vaccines

Since July 2020, the COVID-19 pandemic in China was effectively curbed, resulting in the lack of the conditions for carrying out phase III clinical trial. Hence, Sinovac had to select other countries that feature severe cases and large population and are likely to witness differences in epidemic strains on a global scale to perform large-scale phase III clinical trial, such as Brazil, Turkey, Indonesia and Chile.

On this basis, the research team of Sinovac has successively carried out the real-world study on large samples in Brazil, Chile and Hong Kong and other countries and regions, and simultaneously performed the exclusive safety research for special populations, including people with senile or chronic diseases, pregnant and puerperal women and children. As evidenced by the results of the study, CoronaVac®, the COVID-19 inactivated vaccine developed by Sinovac, is effective in preventing hospitalizations, severe illness, and death.

Simultaneously carry out the phase III clinical trial on efficacy of CoronaVac® while advancing the global layout of CoronaVac®.

Sinovac chooses to conduct clinical research on the same batch of vaccines according to the same immunization procedure in multiple regions with severe disease, large population, and differences in circulating strains in different regions to confirm each other.

- **Brazil 07.21 start**

  Subject population: healthcare workers

  Sample size: 13,060 ⩾ 18 years old

- **Turkey 09.16 start**

  Subject population: healthcare workers + general public (1:9)

  Sample size: 13,000 18-59 years old

- **Indonesia 08.11 Launch**

  Subject population: general public

  Sample size: 1,620 18-59 years old

- **Chile 11.27 start**


  Subject population: healthcare workers + general public (1:10)

  Sample size: 3,000 ⩾ 18 years old

S Plan in Brazil

Serrana, Brazil
SW-CRT
Object of study: with a sample size of around 30,000 (18 years old or above)
Epidemic Area of Gamma Variant

Vaccine Effectiveness(%)		
Symptomatic COVID-19	Hospitalization	Death
80.5 (75.1, 84.7)	95.0 (86.9,98.1)	94.9 (76.4, 98.9)



Real-world study in Chile

Study carried out by the Health Ministry in Chile
Prospective cohort study, covering more than 10.2 million people aged 16 or above in the national healthcare system, and accounting for 80% of the total population
Epidemic area of Gamma variant

Protective effect of CoronaVac® (0.28 Procedure):

Time of Analyses	With Symptoms	Hospita-lization	ICU	Death
1st	67.0%	85.0%	89.0%	80.0%
2nd	65.9%	87.5%	90.3%	86.3%
3rd	63.6%	87.3%	90.0%	86.4%
4th	58.5%	86.0%	89.7%	86.4%

Enhanced immune protective effect due to CoronaVac®:

Booster shot CoronaVac 56% to 80% — For COVID-19 patients with symptoms: increased from 56% to 80%

Booster shot CoronaVac 84% to 88% — For hospitalized COVID-19 patients: increased from 84% to 88%

Real-world study in Hong Kong


The real-world study covers over 1 million cases, among which 5,000 were dead, in the 5th wave of the pandemic in Hong Kong, representing 14% of the local population.
Epidemic Area of the Omicron Variant

	One dose		Two doses		Three doses	
	BNT162b2	CoronaVac	BNT162b2	CoronaVac	BNT162b2	CoronaVac
VE against mild/moderate disease						
20-60 years	37.4 (0.7, 60.6)	2.1 (-53.3, 37.5)	31.0 (1.6, 51.7)	17.9 (-18.0, 42.9)	71.5 (54.5, 82.1)	42.3 (11.4, 62.4)
≥60 years	None[a]	None[a]	None[a]	None[a]	71.6 (43.5, 85.7)	50.7 (12.9, 72.1)
VE against severe/fatal disease						
20-60 years	85.0 (69.1, 92.7)	60.9 (40.6, 74.3)	95.2 (92.9, 96.8)	91.7 (87.8, 94.4)	98.5 (95.9, 99.4)	98.5 (95.2, 99.5)
≥60 years	65.6 (52.4, 75.0)	40.4 (25.9, 52.1)	89.6 (86.2, 92.2)	72.2 (65.5, 77.6)	98.0 (95.9, 99.0)	97.9 (96.1, 98.9)
VE against mortality						
20-60 years	93.7 (74.2, 98.5)	65.4 (38.6, 79.4)	96.4 (93.6, 98.0)	94.0 (89.6, 96.5)	99.4 (95.6, 99.9)	-[b] -
≥60 years	73.0 (60.9, 81.4)	51.2 (38.4, 61.3)	92.3 (89.3, 94.4)	77.4 (71.5, 82.0)	98.1 (95.6, 99.1)	98.3 (96.4, 99.2)

- The protective efficacy of 3 doses of CoronaVac® is superior to that of 2 doses (red frame) among people of different age groups and different degrees of infection
- The protective efficacy of 3 doses of CoronaVac® may be lifted to 98% (green frame) against severe illness / death
- The protective efficacy of 3 doses of CoronaVac® combined with 3 doses of BNT vaccines may be lifted to 98% (blue frame) against severe illness / death

Study among pregnant and puerperal women in Brazil


- A total of 252,430 doses of CoronaVac® were inoculated to the maternal population during the study period; the majority of women vaccinated with CoronaVac® were aged 21-35 (74.06%), predominantly white (40.18%) and brown (29.07%), of whom 76.66% were pregnant women
- The overall incidence of adverse events (AEs) among maternal recipients of CoronaVac® in Brazil was 74.1 per 100,000 doses
- CoronaVac® has the lowest AE rate among four available COVID-19 vaccines in Brazil



Duration: Apr. 1 to Aug. 28, 2021

Phase III clinical trial in Chile

A multi-center, randomized, double-blind and placebo-controlled phase III clinical trial
Object of study: 963 children and adolescents aged between 3 and 17
Epidemic Area of Delta and Omicron Variants



- Immunogenicity: 2 doses of CoronaVac® can remarkably improve the titer of neutralizing antibody against Delta and Omicron variants, and activate T cell-mediated immunity
- Safety: The adverse reaction mainly refers to pain at the inoculation site (mild), and there is no severe adverse reaction

In the meantime, Sinovac has facilitated the registration of CoronaVac® worldwide, and obtained the access approval of 59 countries/organizations/regions within 1 year. Currently, CoronaVac® has been exported to more than 50 countries and regions all over the world with the aggregate amount in excess of 1 billion doses, thus playing a significant role in local COVID-19 prevention and control.

Currently, Sinovac is assisting more countries in achieving local production of inactivated COVID-19 vaccines. To accelerate the equitable distribution of vaccines on a global scale, over the past one year and more, Sinovac has successively made its partners in Africa, Asia and Latin America, including Brazil, Algeria, Egypt, Turkey, Indonesia and Malaysia, eligible for the localized production of inactivated COVID-19 vaccines, and genuinely realized the accessibility to inactivated COVID-19 vaccines and other conventional vaccines in the future worldwide.

Build the Bridge of International Friendship Underpinned by Health

In response to the outbreak and spread of the COVID-19 pandemic, COVAX has been initiated by GAVI, WHO and CEPI to accelerate the development and production of COVID-19 vaccines, and ensure the fair access thereto in all countries. On October 8, 2020, China officially joined COVAX.

As a responsible vaccine manufacturer, Sinovac, on the one hand, makes every effort to ensure the domestic supply of inactivated COVID-19 vaccines and anti-epidemic materials, on the other hand, actively responds to the national call to "make the COVID-19 vaccine a global public product", and promotes the fair distribution of vaccine and international cooperation in anti-pandemic by providing vaccines to aid overseas regions, carrying out technical cooperation and establishing local factories. Globally, Sinovac has supplied more than 41 million doses of inactivated COVID-19 vaccines to 27 countries and regions in Latin America, Europe, Asia Pacific, Middle East and Africa.

Case: The consutruction of "China National Center of BRICS Vaccine R&D Center"



In 2021, Sinovac was entrusted by the Ministry of Science and Technology to undertake the construction of "China National Center of BRICS Vaccine R&D Center", which aims to encourage the associated R&D and trials of vaccines, cooperation for plant construction, authorization for production and mutual recognition of standards among BRICS through online and offline communication.

Over the past 2 years, Sinovac has carried out pragmatic cooperation with Brazil and South Africa in respect of the associated R&D of inactivated COVID-19 vaccines and cooperative production, and yielded plenty of significant achievements. In the future, Sinovac looks forward to further reinforcing the existing good partnership with BRICS and other countries, and continuously expanding the cooperation fields.

50,000 doses of inactivated COVID-19 vaccines were donated to Copa América 2021

In the context that Copa América 2021 was about to be convened as envisaged yet had the competition site changed for multiple times as a result of the raging COVID-19 pandemic, in September 2021, Sinovac donated 50,000 doses of inactivated COVID-19 vaccines to CONMEBOL in favor of the safety of footballers and other staff, ensuring the smooth operation of this exciting tournament.

As an expression of appreciation, Lionel Messi, serving as a Goodwill Ambassador of the United Nations International Children's Emergency Fund as well as a famous football player, presented SINOVAC with 3 jerseys autographed with "con cariño (with love)".


Football delivers health and vaccines spread hope. Against the background of the raging COVID-19 pandemic worldwide, Sinovac, with its mission of "Supply Vaccines to Eliminate Human Diseases" conveyed the confidence of people around the world to overcome the pandemic by getting vaccinated through football.

"That's the best news for CONMEBOL"

——Alejandro Domínguez, Chairman of CONMEBOL



Joko Widodo, President of Indonesia



Recep Tayyip Erdoğan President of Turkey



Sebastián Piñera, President of Chile




Emmerson Mnangagwa, President of Zimbabwe



Luis Abinader, President of Dominican Republic



Anutin Charnvirakul, Deputy Prime Minister of Thailand



Luiz Inácio Lula da Silva, former President of Brazil



Zhong Nanshan, Academician at the Chinese Academy of Engineering

CoronaVac® vaccines have been selected and inoculated by important government members and public figures in many countries/regions



Remain Dedicated to the R&D and Supply of Vaccines for 20 Years

The R&D and supply of vaccines are of utmost significance for eliminating diseases and building a community of common health for mankind. According to the "SDG3 - Good Health and Wellbeing" of the United Nations, great support shall be rendered to the R&D of vaccines and drugs against infectious and non-infectious diseases for the purpose of guarding the public health. In addition, the Outline of the Healthy China 2030 Plan issued by the Central Committee of the Communist Party of China and the State Council also provides explicit provisions on "developing cutting-edge technology for new vaccines, expanding the scope covered by the National Immunization Program, and safeguarding the health of the people".

Resting its corporate development on R&D and innovation, Sinovac remains committed to the R&D and supply of vaccines over the past two decades. In recent years, Sinovac has embraced innumerable achievements in vaccine R&D. Aside from the successful R&D and supply of CoronaVac®, Sinovac's Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains was approved for marketing in 2021; the first bacterial vaccine of Sinovac - 23-valent Pneumococcal Polysaccharide Vaccine was approved for marketing in 2020; in the same year, the only new-generation attenuated varicella vaccine with efficacy proved by phase III clinical results in China was officially marketed for supply, whose R&D adopted the Oka strain of varicella-zoster virus recommended by WHO and SV-1 strain of human diploid cell developed by Sinovac with proprietary intellectual property rights.

Reviwing the development trajectory of Sinovac, it is the social responsibility for controlling diseases through vaccines that serves as an importing driving force for its innovation. Whenever an epidemic breaks out, members of Sinovac always stand at the front line of vaccine R&D without hesitation. The past 2 decades has witnessed the gradual perfection of the disease prevention and control system of China as well as the persistence of members of Sinovac in building an immunologic barrier for more people by virtue of vaccines.

Healive® - Putting an end to the history that China is dependent on the imports of inactivated hepatitis A vaccines

In the twentieth century, numerous Chinese families were plagued by hepatitis A infection. In 1995, the selling price of a dose of the inactivated hepatitis A vaccines imported from abroad equaled to the monthly salary of ordinary people then. In this connection, Mr. Weidong Yin, Founder of Sinovac, determined to research and develop inactivated hepatitis A vaccines for Chinese people. Following four years of unremitting efforts, the inactivated hepatitis A vaccine developed by Sinovac was granted with a "New Drug Certificate" by the National Medical Products Administration, which marked the success of an inactivated hepatitis A vaccine independently developed in China; In July 2002, Sinovac realized the industrial manufacturing of China's first dose of inactivated hepatitis A vaccines, and the marketing of Sinovac's inactivated hepatitis A vaccines at the Great Hall of the People indicated that China would no longer fully depend on the imports of inactivated hepatitis A vaccines. In December 2017, Healive® was pre-certified by WHO and became the first inactivated hepatitis A vaccine who got the pre-qualification in China. Currently, the inactivated hepatitis A vaccine developed by Sinovac is the most widely used hepatitis A vaccine in China, and has the most comprehensive clinical research results. Upon full vaccination, it is able to provide the ongoing protection of 30 years, thus remarkably lowering the incidence rate of hepatitis A in China.

Phase I clinical trial results of the independently developed SARS vaccine were unblinded

The spring of 2003 encountered the outbreak of SARS. In order to develop effective vaccines against SARS, Sinovac facilitated the SARS vaccine research in terms of cell culture, virus inactivation, purification and quality verification based on its complete platform for inactivated vaccine production. Instead of following the conventional research mode, namely, having a single scientist leading a research group to perform a systematic study, Sinovac Beijing, with the substantial support of relevant national departments, played a leading role in integrating the scientific research power of the country, and adopted measures such as "conducting multiple research projects in parallel", "conducting research and production in parallel" and "conducting production and verification in parallel", in a bid to substantially shorten the R&D cycle. In December 2004, less than 18 months from the approval of the research project titled "SARS inactivated vaccine", Sinovac Beijing disclosed the phase I clinical trial results of the independently developed SARS vaccine. It represented a major milestone in China's effort to control SARS and guard the public health. With the end of the epidemic, the development of the vaccine was also terminated, and the strain was sealed.

Influenza A (H1N1) was rapidly overcome

In the spring of 2009, a new type of influenza commonly known as "Influenza A (H1N1)" swept the world, and it was the first time that WHO raised the influenza pandemic alert level to the highest level - level 6. And once again, Sinovac Beijing responded to the epidemic without hesitation. On September 2 of the same year, PanFlu.1®, the split vaccine against influenza A (H1N1) obtained the drug approval number issued by the former China Food and Drug Administration, and the vaccine was then launched in Beijing and other provinces for mass vaccination. It took only 87 days from R&D, pilot production, clinical trial, site inspection, registration and inspection, review and approval to formal approval.

Over the past more than 20 years since its inception, Sinovac has unceasingly diversified its vaccines from the first dose of inactivated hepatitis A vaccines to vaccines against influenza, pneumonia, polio, varicella and COVID-19. Confronted with the outbreak of diversified epidemics in and outside China including hepatitis A, SARS, avian influenza, influenza A (H1N1) and COVID-19, members of Sinovac always stand ready to fight against epidemics and forge ahead. Going forward, Sinovac will continuously take R&D and innovation as the cornerstone, improve the vaccine quality to guard the life of the public with concrete actions to support the construction of Healthy China and the community of common health for mankind.

Excellent Governance to Enhance Sustainable Development

Sinovac has always regarded compliance and stable operation as the cornerstone of the Company's sustainable development. Sinovac has established a systematic and standardized management system and governance mechanism in the fields of compliance and risk control, integrity management and responsible supply chain, promoting high-quality and sustainable development of the Company.




Compliance and Risk Control

Sinovac attaches great significance to compliance and risk control, and is dedicated to building a first-class compliance management system and realizing the excellent compliance management effect. When it comes to the corporate governance, Sinovac standardizes the corporate governance framework in strict accordance with applicable laws and regulations, incorporates compliance management concepts and compliance management mechanisms into corporate governance, and establishes a modern corporate governance system that is scientific, standardized and efficient in operation through rules and systems. As to the corporate operation, Sinovac strictly standardizes the operation compliance in light of the characteristics of its products, and fully satisfies the compliance requirements from multiple perspectives, including criminal compliance, anti-unfair competition compliance, product compliance and data compliance. In addition, the compliance and risk feedback mechanism developed by Sinovac requests all departments to conduct risks evaluation on the compliance level on an annual basis in order to complete the Year-End Summary, thus realizing the effective management of risks.

Compliance Management System

The Compliance Management Committee under the Board of Directors of Sinovac, responsible for governing and leading the compliance management of Sinovac, comprises President & CEO, CFO and Legal Compliance Director of Sinovac, and mainly works out the overall planning and deploys the compliance management of the Company in accordance with the objectives set by the Board of Directors.

Organizational Chart of Corporate Compliance Management




To make Sinovac establish perfect and effective compliance systems, reinforce compliance management, and efficiently identify and proactively prevent and manage compliance risks, the Company has issued documents, including Code of Conduct, Provisions on Compliance Management, Guidelines on Compliance Investigation and Punishment, and Guidelines on Compliance Reporting and Supervision, to provide foundation for the establishment of compliance systems and the formulation of diversified policies. The compliance construction and management of the Company shall adhere to five major principles of independence, compliance with laws, comprehensive compliance, practicability and effectiveness, and scientific innovation, and a long-term compliance risk control mechanism is expected to be established to ensure the legitimate management and compliance operation of Sinovac, and help the Company realize medium and long-term strategic goals.

Launch Multilayered Compliance Training

In 2021, Sinovac continued to firmly advance the construction of compliance culture by arranging 25 compliance trainings for corporate staff, irregularly carrying out multiple specific professional compliance trainings, organizing all the staff to study the compliance management systems, and urging corporate staff to master compliance knowledge and compliance management requirements to develop the compliance and risk prevention concepts. In the future, the Company will continuously reinforce the frequency and intensity of the compliance training and form a compliance culture for all employees of the Company.

Risk Assessment and Self-Inspection

In pursuit of more effective risk management, all departments of Sinovac are requested to organize risk self-inspection, monitor suspicious signs of potential risks events and violations in terms of strategy, operating management and legal compliance, spot contingent risk factors and risk degrees, and work out corresponding risk countermeasures. All departments shall eventually formulate a risk assessment table, which constitutes a complete risk control system.



Integrity Management

Sinovac adheres to the principle of "prevention first, case investigation next (if applicable)", and vigorously advocates the value of integrity. Currently, the Company has realized the strategy and objective of pursuing integrity management by unceasingly optimizing the management policies, enhancing risk prevention and control, and perfecting the management system.

Anti-Bribery and Anti-Corruption


Upholding the faith of respecting integrity, advocating thrift, combating corruption and cracking down on extravagance, Sinovac lays equal stress on education and supervision systems, and comprehensively improves the internal work style from two perspectives, namely, institutional norms and integrity training. Nowadays, the Company has established complete anti-corruption institutions and systems, and issued system paper, including Measures for Donation Management, Measures for Sponsorship Management, and Guidance on the Complianiice of Gifts, Presents and Entertainment, to protect the Company and employees from corruption, bribery, money laundering, unfair competition, insider trading and other illegal conduct, providing basis and institutional guarantee for internal management and supervision. Besides, partners of Sinovac are required to sign the Undertaking for Integrity for the purpose of avoiding all the potential corruption risks.

Diligence to serve the people, integrity to nurture virtues; indifference to fame and wealth to lift the aspiration, thrift to cultivate morality. Now the concept of combating corruption and upholding integrity has become part and parcel of the corporate culture of Sinovac. To ensure the construction of the anti-corruption and integrity culture is effective and accessible, Sinovac has unceasingly launched the training on anti-bribery and anti-corruption for all the staff with a coverage rate up to 100%.

Anti-Unfair Competition

In response to such policies as cracking down on monopoly and unfair competition, Sinovac, as an influential enterprise in the vaccine industry, is dedicated to creating a public, equal and impartial competition climate. Sinovac has regulated unfair competition under the compliance management system, and made anti-corruption clauses and anti-unfair competition clauses a part of the agreements concluded with its partners.





Responsible Supply Chain

Sinovac is clear that building sustainable commercial partnerships is vital to creating a healthy and benign business ecosystem. In this connection, the Company remains committed to establishing a responsible supply chain, and deepening the compliance and quality management of suppliers to ensure the quality of and accessibility to Sinovac's products.

Responsible Procurement

In accordance with the product and business features, the procurement of Sinovac is mainly divided into three types, namely single-source procurement and special procurement, access procurement, and competitive procurement. To improve its capability of responsible procurement, the Company will gradually complete the transition from third-party agent procurement to independent procurement to further enhance its management ability of suppliers.

As an inseparable part of procurement, supplier management is significant for cost control and production and operation guarantee. To reinforce the supplier management and make procurement normative, the Company has issued the Measures for Procurement and Supplier Management that aims to standardize the procurement of the Company.

On the other hand, Sinovac is dedicated to pushing forward the localization and diversification of supply, thus contributing to the development of relevant domestic manufacturers of raw materials and excipients. Exposed to the influence of the raging COVID-19 pandemic worldwide, Sinovac has effectively shortened the procurement cycle, ensured the stability of the supply chain, and guaranteed the stable supply of vaccines while fueling the localization of vaccine raw materials. In addition, the participation of more domestic suppliers also makes the options for the Production Department diversified, and remarkably promotes the upgrade of the industry chain.

Supplier Management

Scientific and strict supplier management can effectively lower the operational risks and ensure the quality of products. To attain the sustainable development of the Company and fulfill its social responsibility, Sinovac has formulated a complete supplier management procedure, and carries out access and routine management assessment for suppliers from the perspectives of evaluation, access, appraisal and elimination.

The fundamental supplier management system of Sinovac integrates qualification verification with site audit to make decisions on the access and evaluation of the supplier from the perspective of quality. On the basis of the previous qualification verification and site audit, the "supplier life-cycle" management mode has been introduced, and the supplier hierarchical recognition system and the supplier evaluation index system have been successively established to improve the supplier evaluation system in a more comprehensive, quantitative and instructive manner.

Sinovac's Supplier Management Procedure

☒Evaluation	Qualification verification is carried out against key material suppliers to ensure their compliance and their supply capacity required by the Company. In accordance with relevant systems for supplier management, the Joint Procurement Center and the Quality Assurance Department and other related departments shall jointly attend the site audit of supplies. Based on the analysis and judgment from the perspectives of material supply risks, difficulty of material/service acquisition and cooperation basis and other perspectives, the hierarchical list is established for the hierarchical administration of suppliers for materials in different types.
☒Access	Suppliers evaluated eligible are requested to sign the Undertaking for Integrity and other agreements to ensure their integrity and compliance prior to their access.
☒Appraisal	14 supplier evaluation indexes are set by dividing weights from four dimensions, namely procurement price level, delivery level, service level and quality situations. And the Demanding Department and the Quality Assurance Department shall be organized to carry out and complete supplier evaluation jointly. In accordance with relevant systems for supplier management, the Joint Procurement Center and the Quality Assurance Department and other related departments shall jointly attend the site audit of supplies.
☒Elimination	In accordance with the evaluation results, the elimination mechanism shall apply to suppliers assessed ineligible.

2021 Supplier Appraisal Quantity


96

2021 Supplier Appraisal Fulfillment Ratio

100 %

To further improve the supplier management level, Sinovac has made unremitting efforts to promote the construction of the procurement information system, apply digital tools for the real-time and coordinated management of supplier's qualification, and request suppliers to report the origin of materials to trace back to the source of manufacturing supplies, which may avoid the procurement of raw materials from regions involved in issues including human right infringement, illicit trading and financing violence, and ensure a secure and reliable supply chain system of the Company.


Information-based Procurement System of Sinovac



For suppliers with poor performance in environment, laborer and morality, Sinovac, in accordance with the provisions on dealing with illegal behaviors committed by suppliers under the Measures for Procurement and Supplier Management, shall terminate its business relations with such suppliers, disqualify such suppliers, delete them from the supplier database, and stop engaging in any business transaction with them within the next 5 years.

Supplier Communication

Pursuant to the development needs, Sinovac has continuously arranged online and offline compliance training for extension service suppliers. By the end of 2021, the Procurement Center had arranged 18 trainings, and organized 20 technical seminars for suppliers. In the future, the Company will continuously expand the coverage of training, optimize the training procedure and contents, improve the value chain level, and accommodate to its development demands.



Continuous Innovation for Better Health

Providing high-quality and affordable vaccines and taking responsibility for disease control to the society is the driving force and pursuit of Sinovac's sustainable development. Since its inception, the Company has continuously strengthened its R&D and innovation capabilities, introducted top talents and resources, and aspired to create more high-quality and affordable products and services to give back to society.



R&D and Innovation

Sinovac regards R&D and innovation as the most significant driving force and social responsibility that underpins its sustainable development. Oriented at the health needs of the country and the public, Sinovac has unceasingly reinforced its R&D capability, developed a core R&D team, and worked hard to manufacture various high-quality and affordable vaccines with the scientific spirit and the pragmatic attitude.

Gather the Strength of Innovation

At the beginning of its incorporation, the Company unveiled China's first Hepatitis A Vaccine (Human Diploid Cell), Inactivated, Healive®, which bridged the domestic gap and contributed to a significant decrease in the incidence rate of hepatitis A in China; subsequently, vaccines developed by Sinovac came out one after another, including China's first and the world's second Hepatitis A and Hepatitis B Combined Vaccine - Bilive®, China's first Pandemic Influenza Vaccine, Inactivated (H5N1), PanFlu®, China's first preservative-free Influenza Vaccine (Split Virion), Inactivated, Anflu®, the world's first H1N1 Influenza A Vaccine (Split Virion), Inactivated, Panfu.1®; Enterovirus Type 71 Vaccine (Vero Cell), Inactivated, Inlive® – the world's first preventive first-in-class biological products; Influenza Vaccine (Split Virion), Inactivated, Quadrivalent; Varicella Vaccine, Live; Mumps Vaccine, Live; 23-valent Pneumococcal Polysaccharide Vaccine and Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains. On February 5, 2021, CoronaVac®, the COVID-19 inactivated vaccine developed by Sinovac, was approved for conditional marketing in China, which obtained the access approval from 59 countries/organizations/regions by the end of 2021.

From isolating TZ84 strain of the hepatitis A virus to analyzing crystal structure of hepatitis A and EV71, from overcoming SARS and H1N1 influenza A to fighting COVID-19, members of Sinovac always prioritize the health needs of the the country and the masses, and never cease their innovation. During this process, Sinovac has successively undertaken near 60 national and local scientific research projects, including the National Key Technologies R&D Program of China, 863 Program, Major Special Project for New Drug Development and Major Special Project for Infectious Disease Prevention and Control and other projects, obtained 4 national science and technology awards and 5 provincial science and technology progress awards, and applied for over 130 patents among which more than 80 were authorized. Amid more than 70 SCI papers of its research achievements, multiple are published on well-known academic journals, such as *The New England Journal of Medicine, The Lancet, Nature* and *Science*.

Sinovac always lays emphasis on R&D and innovation. Up to now, the Company has developed diversified technical platforms for the R&D of inactivated vaccines, viral vector vaccines, live attenuated vaccines, genetic engineering vaccines, bacterial polysaccharide-protein conjugate vaccines, combined vaccines and mRNA vaccines, etc., mastered a number of core technologies in terms of construction of bacteria strains, large-scale microcarrier culture, polysaccharide/protein purification, binding and formulation, etc., and formed relatively stronger synergistic effect with the Chinese nationa Center of BRICS Vaccine R&D Center, Beijing Enterprise Technology Center, Beijing Engineering Technology Center of Novel Vaccines, Post-doctoral Research Center and other platforms to continuously enhance its hard power of R&D and innovation. Thanks to the foregoing platforms and core technologies, the Company is engaging in the R&D of various vaccines with proprietary intellectual property rights and reaching internationally advanced level such as DPT combined vaccines, HFMD vaccines, pneumococcal vaccines, live attenuated vaccines against MMR, herpes zoster vaccine, cell-based flu vaccines and respiratory syncytial virus vaccine.



Certification of Sinovac LS as "National High-Tech Enterprise"



Certification of Sinovac Beijing as "National High-Tech Enterprise"



Certification of Sinovac Dalian as "National High-Tech Enterprise"

Stress on the Cultivation of R&D Talents

Given that talents are the source of innovation, the Company attaches great significance to the R&D talent echelon construction and cultivation to develop a talent team accommodating to the market competition and satisfying the corporate development demands through a combination of external introduction and internal training.

Currently, Sinovac boasts a R&D team of more than 400 members. Within the Company, it, taking Sinovac Academy as carrier, establishes the training system comprising lecturing by internal lecturers, online and offline training for employees and rotational practice to provide employees of different ranks with the learning path. Outside the Company, it, through the cooperating training mechanism with well-known colleges and universities, reinforces the recruitment and cultivation cooperation mechanism targeting graduates with bachelor, master and doctoral degrees, links employees' study with talent development by unveiling Sinovac Progress Award and other means, and empowers employee to carry out their roles for personal development to guarantee a continuous growth of talents essential for the implementation of the R&D strategies. Furthermore, it encourages the technological development by means of introducing high-level talents both at home and abroad and recruiting experts to carry out technology import proactively.

Inspire Innovation Vitality

In pursuit of the further enhancement of innovation capability, Sinovac has formulated a number of reward and incentive mechanisms while remarkably increasing the scientific research input, so as to inspire innovation vitality.

Sinovac launches the R&D dual-channel development path within the Company, and provides the R&D personnel with the development channel of technical route under the Administrative Measures for Qualification within the R&D System. To encourage the independent innovation, Sinovac Beijing issues the Incentive Measures for Patent Application, according to which employees will be rewarded based on their achievements in the scientific research. In the meantime, Sinovac Dalian works out a series of systems, including Administrative Measures for Academic Papers and Administrative Measures for Releasing Academic Papers and Applying for Patents, to provide employees and authors of academic papers with due awards. Through 2021, Sinovac Beijing, Sinovac LS and Sinovac Dalian are granted with 8, 4 and 1 authorized patent(s) respectively.

In addition, the Company has also cooperated with experts from domestic and overseas universities, institutes, scientific research institutions and medical institutions to support the effective operation of existing platforms and ensure the rapid R&D of various products. Meanwhile, Sinovac has set up the Scientific Committee within the Company to introduce scientists, and developed the Special Training Program for scientific research talents and provided scientific research funds for the introduced personnel, allowing them to give full play to their strengths, jointly overcome key technical challenges in the industry, and facilitate the stable improvement of overall scientific research technology and research level.

Vaccine Quality and Supply

Adhering to the enterprise mission of "Supply Vaccines to Eliminate Human Diseases", all companies of Sinovac pay due attention to product quality, strictly implement applicable laws and regulations, proactively respond to various new requirements under the *Drug Administration Law of the People's Republic of China*, the *Vaccine Administration Law of the People's Republic of China* and *the Biosecurity Law of the People's Republic of China*, improve the quality management technology and level, and strictly control all aspects of vaccine R&D, clinical trials, production and transportation etc., all for the purpose of ensuring the safety, efficacy and controllable quality of vaccines, and continuously delivering high-quality vaccines to domestic and overseas markets.

Improve the Quality Management System

To ensure the product quality, Sinovac has established the complete management regulation on quality policy, clarifying the quality policy in four aspects: resource guarantee, full involvement, continuous improvement and environmental friendliness, and developed the quality management system covering the entire product life cycle from drug R&D, technology transfer, commercial production to product termination in accordance with the *Good Manufacturing Practice (GMP) for Drugs* in China, *World Health Organization (WHO) GMP* and *International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q10*. The risk management is fully implemented at each stage to ensure the effective operation and continuous improvement of the quality system, and to improve the quality control throughout the value chain of products.

Quality Policy Applying to All Companies of Sinovac	
Resource guarantee	It's impossible to carry out any quality work without the establishment and effective operation of the quality management system, for which senior managers of the Company are expected to channel enough and essential resources to support the establishment and operation of the quality management system.
Full involvement	Quality management gets all departments of the Company involved and runs through the entire product life cycle, for which all staff shall undertake their respective duties for quality management to ensure the achievement of quality objectives at different stages, including product R&D, technology transfer, commercial production and product exit.
Continuous improvement	Continuously improved means shall be adopted to further perfect the quality management system and optimize the manufacturing process, thus attaining the unremitting improvement of product quality, and yielding higher customer satisfaction.
Environmental friendliness	Apart from ensuring product quality, Sinovac also has a duty to take care of the environment quality in and outside the Company, and shoulders the responsibility for protecting personnel health and natural environment from any damage as a result of its production or any other activities.

Comprehensive System Quality Control

For the purpose of "establishing an international and collective quality management system, and building an international quality brand", Sinovac further decomposes its quality objectives for better implementation. For instance, all companies of Sinovac formulate diversified systems, including *Quality Policy of Sinovac Biotech Co., Ltd., Quality Principles and Objectives of Sinovac Biotech Co., Ltd., Quality Policy of Sinovac Life Sciences Co., Ltd., Quality Principles and Objectives of Sinovac Life Sciences Co., Ltd., Quality Policy of Sinovac (Dalian) Vaccine Technology Co., Ltd. and Quality Objectives of Sinovac (Dalian) Vaccine Technology Co., Ltd.*, to elaborate quality objectives, starting from the key aspects of the comprehensive system from the product R&D to the transportation, in the form of quality principles.

As requested by the Company, all the work at the product R&D stage shall be subject to the fundamental principle that "quality originates from design". During the product R&D process, in this connection, the Company fully considers the inherent quality of products, feasibility and controllability of future industrialization, and quality comparability with similar products in foreign countries to ensure that the high-quality is "designed" into the product. Sinovac emphasizes "forward-looking" product "quality design" to continuously ensure the product quality, considering the time span from R&D to production and the environmental changes within three to five years, including amendment to drug regulatory laws and regulations and quality improvement of competitors' products and other changes.

At the production stage, all companies of Sinovac has established a complete GMP quality management system conforming to applicable laws and regulations. Within all the GMP workshops designed and constructed according to the international standards and the GMP requirements, Sinovac uses advanced domestic and international facilities and equipment, organizes production and verification in strict accordance with the GMP of the PRC, adopts advanced management concepts of WHO GMP, EU GMP, America cGMP, and make the entire production process meet various GMP requirements at home and abroad to guard the quality of vaccines. At the stage of vaccine manufacturing, the Company formulates quality standards and production process procedures for vaccines at different stages pursuant to the product registration regulation to ensure the "controllable process and desired quality" of vaccines.

At the stage of clinical trials, the Company carries out the clinical trials of products in strict accordance with WHO-PQ and relevant clinical trial guidelines in and outside China to ensure reliable clinical outcomes and sufficient evaluation of product quality.

At the stage of transportation, the Company is equipped with the cold-chain temperature control facilities and equipment with high standards and stable performance, and carries out effective control on all stages, such as vaccine sales, warehousing and distribution, in strict accordance with GMP and GSP requirements to ensure the whole-process quality safety and information traceability of vaccines.

In 2021, the lot release qualification rate of finished products of Sinovac Beijing and Sinovac Dalian reached 100%, and the qualification rate of the inactivated COVID-19 vaccines of Sinovac LS approved for emergency marketing also achieved 100%.

In 2021, the varicella vaccine developed by Sinovac Dalian passed the WHO-PQ site inspection, serving as another important milestone for the internationalization of corporate products.

All products marketed by Sinovac Beijing are certified with the national GMP or passed the GMP inspection on compliance, among which vaccines against hepatitis A and other diseases are certified with the GMP of Brazil, Russia, Argentina and Turkey and other countries, and Hepatitis A Vaccine (Human Diploid Cell), Inactivated, Healive® is the only hepatitis A vaccine in China that passes the WHO-PQ assessment.


In 2021, Sinovac LS organized the site inspection of the phase II and III bulk workshops for registration and production of COVID-19 vaccine, multiple GMP inspections, WHO PQ inspection and GMP certification by multiple foreign countries for 391 times in the aggregate, completed the verification of newly-built plants, quality control labs, material warehouses and cold room with a total of 5086 items, fully ensured the legality and compliance of COVID-19 vaccine production, and obtained recognition nationwide and from WHO and other countries/regions/organizations worldwide.

Impose strict control over quality to ensure the safety and efficacy of each vial of CoronaVac®

As a result of the raging COVID-19 pandemic worldwide, the domestic and international demand for the inactivated COVID-19 vaccines is unceasingly soaring. While stepping up production to ensure sufficient vaccine supply, Sinovac LS unswervingly upholds the underlying operation logic of "guarding biosafety and product quality; practicing its mission and benefiting the world" for continuous control of product quality.

All departments of Sinovac LS carry out division of duties in accordance with relevant businesses, establish 15 microcirculation working groups with process as the minimum unit, and form product segments through organic connection among groups. From material input to process control, and to product delivery, there are 3,422 control points along the product line, and each vial of CoronaVac® is the R&D outcome of the whole chain input and tens of thousands of times of quality control. Aside from the sampling inspection and manufacturing supervision carried out by quality system departments, the COVID-19 inactivated vaccine Department (CVD) also establishes an internal process group, develops the self-inspection and self-correction mechanism, summarizes manufacturing parameters and quality inspection results, and tracks and monitors the process stability to enhance the manufacturing compliance.

Through 2021, the Company saw the vaccine bulk production of more than 400 batches with the lot release qualification rate reaching 100%, which indicates stable product quality and controllable risks, further ensuring the safety and efficacy of each vial of CoronaVac®.



Ensure Product Supply

Due to the influence of the COVID-19 pandemic, in 2021, raw material suppliers were plagued by such problems as deficient supply and longer lead time. To ensure the sufficient and stable supply of vaccines, all companies of Sinovac formulated detailed and comprehensive management provisions in accordance with the national anti-epidemic policies, combining their enterprise characteristics. Based on the prediction and dynamics of product demands, they adjusted the production plan by increasing raw material suppliers of some products, and optimizing production scheduling to avoid the influence of supply shortage on production progress. In addition to satisfying domestic and overseas orders, they also established the safety inventory of vaccines for unexpected demands and to fully guarantee the vaccine supply.

To ensure the sufficient supply of inactivated COVID-19 vaccines, all departments of Sinovac LS, holding its core objectives of" full-speed productin with high-quality", worked together and spent one and a half years in completing the construction of 12 bulk production lines, 16 filling lines and 19 packaging lines and large-scale production in a rapid and high-quality manner, realizing a production capacity of over 2 billion doses.

On the other hand, ongoing efforts were made by Sinovac to improve the process of all production lines, carry out information-based construction, further enhance the production capacity and ensure the efficient and stable supply of products.

Sinovac Beijing's Project for Higher Production Capacity of sIPV Bulk

In response to the Global Polio Eradication Initiative (GPEI) of WHO, Sinovac Beijing initiated the sIPV project, taking" provide vaccines eliminating polio for human beings" as its goal. Therefore, the sIPV vaccine developed by Sinovac Beijing targets children worldwide. In order to meet the global demand for sIPV, the IPV Division of Sinovac Beijing studied how to improve the production capacity of sIPV bulk. It also carried out the process validation study on expanding the cell resuscitation culture scale, which enabled the IPV Division to better contribute to GPEI on behalf of Sinovac and China.

Customer Service

Due to its stress on customer service, Sinovac establishes the active after-sale service system over the years to continuously improve the customer service level. In order to quickly gather and respond to user's service requirements, special persons are arranged by sales and other relevant departments of Sinovac to maintain normal contact with customers, so as to know product flow and vaccination rate timely, and monitor adverse reactions.

Furthermore, an official account is established and 400 enquiry service hot-lines are released to respond to relevant questions and consultation. In the meantime, Sinovac, through the official account of" Benefit of Vaccine" , proactively popularizes anti-epidemic knowledge, responds to questions raised by the masses, and organizes knowledge lectures and training, in a bid to improve the satisfaction of production, management and customer.

Sinovac protects the rights and interests of customers through emergency disaster response

For products of Sinovac, it usually takes 4 days from placing an order to the product is signed-for. The Company attaches great significance to product quality, and proactively safeguards the rights and interests of customers. For instance, the flood hitting Henan province in 2021 resulted in the outage of our customers' refrigeration equipment and the soaking of 19,385 doses of vaccines in 20 districts and counties. After informed of the disaster, Sinovac immediately established an emergency relief team, took the initiative to contact customers, carried out quality and safety evaluation for disaster-affected vaccines, and duly completed disposal thereof as required by customers.

Customer Service System

The Company establishes a comprehensive service system to provide customers in and outside China with pre-sale, sales, after-sales service and other whole chain services. To control the product quality, the Company has the Quality Assurance Department performing whole-process monitoring on production, delivery and packaging of products. Prior to the delivery, the Company carries out self-inspection of the goods, and equipped it with a product quality certificate issued by relevant national departments. For overseas customers, the Company prepares products in strict accordance with respective requirements for product registration and approval in the targeted countries, including but not limited to requirements in terms of workshop, production line, dosage form, packing materials and expiry date, etc.

Protection of Customers' Rights and Interests

Sinovac has established a comprehensive return and exchange system to safeguard the rights and interests of customers. Besides, it formulates and issues a series of standardized process systems, including *Specifications for the Investigation* and *Disposal of Adverse Reactions/Events* and *Products Involved*, *Specifications for Product Changing & Refunding* and *Specifications for Complaints Handling*, to proactively protect the legitimate rights and interests of customers. After receiving any complaint about its products or any return and exchange application, the Company will carry out standardized operation pursuant to the foregoing specifications. Furthermore, Sinovac has taken out insurance from The People's Insurance Company of China Limited (PICC) against "adverse events following immunization" of vaccines manufactured by Sinovac, so as to fully guarantee the rights and interests of customers.

In the meantime, the Company emphasizes the protection of customer information, strictly implements systems pertaining to the privacy of customer archives and confidentiality of sales data, and urges employees in posts relating to the security of customer information to sign the confidentiality agreement as required. And the departments of the above mentioned employees has formulated the Specifications for the Qualification Review of Customers and Procurement Personnel, and irregularly launches sales and marketing training to avoid customer privacy disclosure.

Stress on Pharmacovigilance Management


All companies of Sinovac pay great attention to pharmacovigilance management, and strictly comply with such rules and regulations as *Vaccine Administration Law, Specification for Pharmacovigilance Quality Management, Measures for the Reporting* and *Monitoring of Adverse Drug Reactions, National Monitoring Scheme for Suspected Adverse Events Following Immunization* and *Notification of the National Medical Products Administration on Direct Reporting of Adverse Events by Drug MAHs.*

A special pharmacovigilance team, taking charge of pharmacovigilance of vaccines during their whole life cycle, is established by Sinovac to fully ensure the medication safety of inoculators, direct the rational use of drugs, minimize the safety risks of drugs, protect and facilitate public health, and analyze and deal with suspected adverse events following immunization, Besides, the Company has established a comprehensive pharmacovigilance system and quality management system, and develops rules and regulations like *Organizational Structure and Duties of the Pharmacovigilance Management System and Handbook of Pharmacovigilance Management*, which clarify work objectives, management principles and quality control, stipulate the organizational structure, management requirements and technical requirements of the Company's pharmacovigilance system, back up the formulation of documents at all levels in the Company's pharmacovigilance system, and direct the Company to carry out pharmacovigilance work from the perspective of institutional system.

When it comes to the management of and response to safety information, the Company formulates the *SOP for the Collection and Reporting of Safety Information, SOP for the Collection and Reporting of Overseas Adverse Events and the Collection and Disposal of Adverse Reactions/Events during Clinical Trials or upon Marketing* and other documents, which stipulate the manners and principles of collecting and reporting vaccine-related safety information in and outside China, and realize the effective collection and disposal of adverse events during clinical trials or upon marketing at home and abroad. Specifically, safety information shall cover the whole life cycle of vaccines from R&D to marketing, safety-related data shall be collected in a comprehensive, systematic and timely manner, and periodical safety update reports shall be submitted to drug regulatory authorities in accordance with the SOP for the Regular Safety Update Report to achieve timely and effective data processing and analysis, signal identification and response.

In addition, all companies of Sinovac launch pharmacovigilance training from time to time for the purpose of strengthening the risk prevention and control awareness of each department, making timely response while ensuring compliance, and effectively safeguarding the health and safety of users. Through 2021, Sinovac carried out pharmacovigilance training for 13 times in total.





Communion and Co-Construction Create Shared Value

Thanks to its own R&D advantages and industry resources, Sinovac integrates its social responsibility with industry cooperation, proactively organizes and participates in industry communication, and remains dedicated to building the mutual benefit and win-win industry ecology, and enhancing the sound development of the industry. In the meantime, Sinovac is active in attending international exchange and cooperation for the purpose of enhancing the driving force of the domestic vaccine and health industry, enhancing the sound development of the industry, and enabling the international society to realize mutual benefit and win-win results.



Promote the Sound Development of the Industry

As a national biological high-tech enterprise, Sinovac has made aggressive efforts to explore the developing direction, fuel technological innovation of the industry, and contribute to a higher prevention and treatment level of infectious diseases at home and abroad.

Fuel Industry Development

To fuel the common development of the industry, Sinovac establishes strategic cooperation relations with disease control and prevention units, collaborates with academic institutions to carry out special research, and proactively organizes academic exchange summits for high-quality talents. Relying upon its training platform, the Company has developed a training system, providing experts and lecturers with support, and reserves talents for the further development of the disease prevention and control cause. In 2021, Sinovac signed the strategic cooperation agreement with 12 provinces and 14 prefecture-level cities, and deepened the cooperation with them in the fields of vaccine supply guarantee, cold chain construction, academic research, talent cultivation and health education and others.

In the meantime, Sinovac proactively performed business cooperation and innovation with key enterprises at the upstream and downstream of the value chain such as R&D, transportation and inoculation, so as to provide safe and reliable vaccines, and guard life health.

Help Suppliers Improve Quality

Filters are important materials for the production of Sinovac's vaccine bulk.As a result of the outbreak of the COVID-19 pandemic worldwide, filters once saw short supply at the beginning of 2021.Against the background, the Procurement Department and the Production Department of the Company rapidly responded thereto, established cooperative relations with more domestic manufacturers, proactively communicated with them and remarkably lift the usage rate of domestic filters in key process by verifying the feedback to come up with suggestions.

Launch Benchmarking Services of Vaccine Cold-chain Distribution

Vaccines, as a special drug, have extremely high requirements for transportation environment and efficiency, and stable and efficient logistics distribution service is vital to guarantee the vaccine quality. To optimize the transportation of vaccines and ensure the product quality, Sinovac carries out active cooperation with first-class distributors in the transportation industry, contributed to the construction of the domestic vaccine distribution network.

On the premise of conforming to laws and regulations at home and abroad, both parties proactively develop diversified cooperation patterns on fronts of vaccine circulation, cold chain technology, cold chain storage and transportation, etc., offer advice for industry regulations based on their abundant experience, and facilitate the development of the vaccine cold chain distribution industry.



Develop the Digital Platform of "Internet + Vaccine"

In the context that epidemic prevention and control become the new norm, a growing number of people realize the significance of vaccination. And if the whole process of each vaccine from development to vaccination is recorded by the Internet, the effect of "one person, one vaccine" can be tracked for a long time to guard the health of the masses.

In this connection, Sinovac carries out proactive cooperation with digital massive health platforms to build the vaccination platform of COVID-19 vaccines by digital means, which includes online reservation for vaccination, "inoculator - vaccine" information matching based on digital traceability code, follow-up visit of post-vaccination health condition, and issuance of vaccination certificate. Currently, some high-risk populations are able to make vaccination reservation of COVID-19 vaccine and enjoy follow-up services on such platform.

Further efforts were made by Sinovac to explore the innovative application of the digital platform of "Internet + vaccine", such as science popularization of vaccines, for the purpose of continuously increasing the accessibility to vaccines in China, encouraging the development of the biopharmaceutical field, and driving the upgrade of the massive health industry.

Establish Strategic Cooperation with Sichuan Province and Render Vigorous Support to the Construction of the Public Health System from "Reviving the West"

The MOU on Strategic Cooperation concluded by Sinovac and Health Commission of Sichuan Province in August 2021 marked the establishment of the comprehensive strategic cooperative partnership between them. Subject to the direction of "reviving the west", both parties will make full use of their advantages in respective fields, deepen their cooperation in terms of public health echelon talent cultivation, clinical trial and research, public education, public welfare publicity and ensuring public supplies of vaccines, introduce brand-new public health cooperation patterns, enhance the economic development in western regions, reinforce the public health, and achieve the ambitious goal of "Healthy China" soon.

Drive Industry Exchange

In order to facilitate industry information exchange and cultivate industry talents, Sinovac proactively attends industry exchange, convenes or undertakes domestic and overseas academic exchange conferences in collaboration with industry associations and authoritative institutions to share industry experience and knowledge, and enable technical improvement and industry upgrading.

Presence at the 2021 Annual Meeting of Beijing Pharmaceutical Association on Invitation

On December 11, 2021, Mr. Weidong Yin, Chairman, President & CEO of Sinovac, attended the Annual Meeting of Beijing Pharmaceutical Association on invitation, and addressed a keynote speech titled "Contributions of Chinese Vaccines to the Global Anti-epidemic Endeavors". Specifically, Mr. Weidong Yin introduced the R&D, industrialization, international registration and international supply of Sinovac's COVID-19 vaccines in a systematic manner in combination with the national reforms on pharmaceutical review and approval systems in recent years.



Convening the 2021 Seminar on the Respiratory Infectious Disease Prevention and Control Strategies against the Background of the COVID-19 Pandemic as the Undertaker

On October 16, 2021, the 2021 Seminar on the Respiratory Infectious Disease Prevention and Control Strategies against the Background of the COVID-19 Pandemic, headed by Chinese Preventive Medicine Association and undertaken by Sinovac, kicked off in Nanjing as envisaged, where Sinovac demonstrated the real-world research progress of its inactivated COVID-19 vaccines, and promised to continuously carry out the clinical research on the combined immunization of the inactivated COVID-19 vaccine, influenza vaccine and 23-valent pneumococcal polysaccharide vaccine, and render research support to the respiratory infectious disease prevention and control against the background of the COVID-19 pandemic.




Proactively Carry out International Cooperation

Diseases know no country. Confronted with the raging COVID-19 pandemic worldwide, all the countries constitutes the community with a shared future. In this context, Sinovac, proactively responding to the six-point Global Vaccine Collaboration Action Initiative proposed by the Chinese government, thoroughly implements the principles of international cooperation, pools the strength of multiple parties for the long-term development of R&D and innovation, bridges the global immunization gap, endeavors to build the community with a shared future for mankind, and performs practical actions to ensure the equitable distribution of vaccines and promote the global anti-epidemic cooperation.

Practicing its mission of "Supply Vaccines to Eliminate Human Diseases", Sinovac makes active efforts to build partnerships with a number of international institutions. Currently, as a member of Developing Countries Vaccine Manufacturers Network (DCVMN) and International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Sinovac collaborates with WHO, UNICEF and Pan American Health Organization (PAHO) and other international health organizations to jointly resolve problems in the global public health field. In 2021, Sinovac provided one tenth of its total vaccines through COVAX headed by GAVI and other organizations, and facilitated the fair accessibility to vaccines with its concrete actions. Besides, Sinovac's Brazilian partner Dimas Covas, Director of the Butantan Institute, Professor of the University of São Paulo, and Head of Sinovac's Clinical Research Project in Brazil, was awarded the "Friendship Award" by the Chinese government.

"Phase III clinical trial of CoronaVac® in Brazil, Turkey, Indonesia and Chile etc. and subsequent real-world research are the global collaboration paradigm on fighting the COVID-19 pandemic in a scientific manner, laying a solid scientific foundation for enabling CoronaVac® to be recognized by WHO based on its approval obtained in over 50 countries and regions worldwide."

——Mr. Weidong Yin, Chairman, President & CEO of Sinovac



Promote International R&D Exchange Based on Own Resource Advantages

International academic exchange is critical to the technological innovation in the biopharmaceutical industry. Underpinned by own resources, Sinovac proactively participates in international top-level dialogues, and builds bridges for global medical academic exchange. From international academic exchange to performing cooperative clinical trials at the R&D stage and providing aids through vaccine production and export, and to cooperative vaccine production, Sinovac carries out international cooperation and exchange during the whole product chain of vaccines.



Convening the International Academic Exchange Conference on Phase III Clinical Studies of CoronaVac, Sinovac's Inactivated COVID-19 Vaccine and Related Application

To enhance industry exchange and promote the development of the international vaccine cause, Sinovac convened the International Academic Exchange Conference on Phase III Clinical Studies of CoronaVac, Sinovac's Inactivated COVID-19 Vaccine and Related Application twice (in March and November of 2021 respectively), where clinical research data and academic achievements of CoronaVac® were shared and exchanged, and discussions about the status quo and development prospect of vaccines against the background of the raging COVID-19 pandemic worldwide were carried out.

The conference was well attended by ambassadors to China and counselors of 22 countries as well as multiple experts from Chinese Center for Disease Control and Prevention. In addition, the conference saw the online presence of experts and scholars from 42 countries and international organizations as well as over 2,000 experts from domestic centers for disease control and prevention at different levels.



Presence at the International Forum on COVID-19 Vaccine Cooperation on Invitation

On August 5, 2021, the first International Forum on COVID-19 Vaccine Cooperation, themed by "Strengthening international vaccine cooperation to drive the equitable distribution of vaccines worldwide", kicked off, and saw the presence of Wang Yi, State Councilor and Foreign Minister of China, Vice Prime Minister, Foreign Minister, Health Minister or senior representative of many countries including Thailand, Uzbekistan and Russia, head of international organizations like UN, WHO, GAVI and CEPI, and representatives of 29 vaccine enterprises in and outside China, where 23 participating countries jointly released the joint statement of International Forum on COVID-19 Vaccine Cooperation.

In attending the Forum, Sinovac reported the latest research and application achievements of CoronaVac®, indicated that it would submit to the drug regulatory authority of each country the application for clinical research and emergency use of CoronaVac® against new COVID-19 variants, and showed its expectation to collaborate with other countries for scientific research and supply of vaccines, to further enhance the safety of vaccines and lift the vaccination rate.



The International Forum on COVID-19 Vaccine Cooperation

Presence at 2021 J.P. Morgan Healthcare Conference, Shanghai Forum on Invitation

October 12, 2021 saw the convening of J.P. Morgan Healthcare Conference, Shanghai Forum, themed by "Vaccine Development: Post-Pandemic Life – Enter into the New Era", where Sinovac shared its rapid decision-making, R&D and production of inactivated COVID-19 vaccines and ascribed those achievements to its abundant experience and talent reserve accumulated as a result of developing vaccines to respond to the sudden outbreak of various emerging infectious diseases over the past 20 years. In the future, Sinovac will continuously focus on the development of vaccines against emerging infectious diseases and infectious diseases with sudden outbreak, strive for the technological upgrade and industrial upgrade of existing vaccines, and lower the incidence rate of various diseases by increasing the vaccination rate of vaccines.

Presence at the Online Academic Exchange Conference of "COVID-19 Vaccination - The Hong Kong Perspective" on Invitation

June 5, 2021 encountered the 100th day that Hong Kong officially initiated the vaccination of COVID-19 vaccines. To facilitate the exchange and cooperation between Hong Kong and Chinese Mainland with respect to the research and vaccination of COVID-19 vaccines, and further inform Hong Kong residents of COVID-19 vaccines, the Hong Kong Medical Association particularly organized and convened the Online Academic Exchange Conference of "COVID-19 Vaccination - The Hong Kong Perspective".

While attending the Conference, Sinovac introduced the clinical and real-world research progress of CoronaVac®, reviewed the safety and immunogenicity results of its phase I/II clinical research as well as the results of its phase III clinical cooperative research performed in Brazil, Chile, Indonesia and Turkey etc., and interpreted the real-world research results of CoronaVac® released by countries like Chine, Brazil and Uruguay. As evidenced by those research results, CoronaVac® features excellent safety and protective effect, and is especially effective in preventing severe illness and death.



Sinovac's Vaccines Enabled Serrana, A Small Town in Brazil, to Become an "Oasis against the COVID-19 Pandemic"

Serrana, a small town in São Paulo, is dubbed as the "model city of fighting the COVID-19 pandemic" in Brazil.

At the beginning of 2021, Serrana, as other cities in Brazil, was plagued by the resurgence of the COVID-19 pandemic. Many local people were infected with COVID-19, and more than 80 deaths were reported. Medical workers were terribly fatigued, and the medical system was on the verge of collapse.

Upon initiation of the vaccine trial "S Plan" by Sinovac and Instituto Butantan situated in São Paulo, the epidemic in this locality was effectively curbed. Since the beginning of February 2021, residents in Serrana were successively vaccinated with Sinovac's vaccines with a total number of 27,150, representing 60% of the total population. With the advancement of the "S Plan", the number of both registered people in urban hospitals and severe cases declined remarkably. Upon completion of full vaccination in April, there were only 1-2 cases of death, both of which were infected with COVID-19 prior to vaccination.

The life in Serrana finally resumed as usual, with the people back on streets and restaurants and shops bustling again. According to local residents, "China's vaccines are the most wonderful gift we've received".

"It is the inoculation of Sinovac's vaccines that ignites the hope of life of ordinary people, and makes them feel relieved and secure."

——Léo Capitelli, Major of Serrana

Make Vaccines More Accessible Worldwide by Enhancing the Global Production of Vaccines

As a responsible vaccine manufacturing enterprise, Sinovac, proactively responding to the national call, unswervingly stands at the front line of international epidemic prevention, makes vaccines more accessible worldwide, and joins hands with other parties to jointly safeguard the life and health of people all over the world. To fulfill the cooperation agreement of vaccine supply concluded with COVAX in July 2021, Sinovac relieves the COVID-19 prevention and control pressure, and contributes to the equitable distribution of vaccines by providing developing countries with vaccines.

As the global demand of COVID-19 vaccines exceeds the global supply thereof, the local production of COVID-19 vaccines in a timely and reliable manner is of utmost significance. To ensure the timely vaccination in developing regions, Sinovac, aside from the direct assistance or donation of vaccines, also set vaccine manufacturing plants or conducted technology transfer and cooperative production in multiple countries and regions including Latin America, Asia Pacific, Middle East and Africa, with a view to enhancing the localized production of vaccines and remarkably improving the accessibility to and affordability of vaccines in developing countries. In 2021, Sinovac dispatched more than 50 key talents of overseas projects to Chile, Turkey, Algeria, South Africa and Thailand etc. to ensure rapid and effective implementation of the vaccine localization projects there.

Promote Vaccine Local Manufacturing and Filling in Malaysia

The cooperation agreement on inactivated COVID-19 vaccines concluded by Malaysia-based Pharmaniaga and Sinovac in January 2021 realized the ultimate manufacturing and filling of local vaccines in Malaysia.

After reaching cooperation, Sinovac, in addition to supplying vaccine bulk, also provided Malaysia with technical support and knowledge sharing in different ways, such as dispatching experts. Due to the non-stop operation (24 hours a day and 7 days a week), the factory accomplished the task of offering 14 million doses of local filled CoronaVac® to cater to the National Immunization Program in Malaysia in advance.



Enable the Vaccine manufacturing in Egypt and Assist Egypt in Building a Fully-Automated Cold Room for Vaccine

After reaching a strategic cooperation with Egypt, Sinovac provided 1,400 liters of Sinovac's vaccine bulk, which may be used to manufacture 2 million doses of inactivated COVID-19 vaccines. In addition, relevant technical personnel have been dispatched by Sinovac to direct and supervise the filling and packaging etc. of vaccines in Egypt, and to guarantee the implementation of local manufacturing and filling of vaccines in a safe and effective manner. Currently, Egypt has completed manufacturing the first batch of 1 million doses of vaccines. To help Egypt further enlarge its production capacity, Sinovac will accumulatively provide it with 26,000 liters of vaccine bulk. Besides, Sinovac has signed an agreement with Egypt to aid its construction of a fully automated cold room, which is able to store 150 million doses of vaccines upon construction and will become the largest vaccine storage center in Egypt and even Africa.



Contribute to building the "ASEAN-China Health Shield"

At the 2021 Special ASEAN-China Summit to Commemorate the 30th Anniversary of ASEAN-China Dialogue Relations, China initiated the "ASEAN-China Health Shield" cooperation initiative. In response to the initiative, China, in addition to aiding ASEAN countries with 150 million doses of inactivated COVID-19 vaccines free of charge, will ramp up the joint production of vaccines with and the technology transfer to ASEAN countries, and carry out R&D cooperation of key drugs with them to improve their independent guaranteed level.

To earnestly implement the "ASEAN-China Health Shield" initiative, Sinovac has carried out relevant research on and local production of inactivated COVID-19 vaccines with the government, research institutions and enterprises etc. in ASEAN countries, and made aggressive efforts to build vaccine manufacturing factories in ASEAN countries with a view to developing a firm supply chain system in the manner of "quenching immediate thirst with water nearby" and ensuring the stable supply of vaccines to ASEAN countries by "teaching them how to fish".

Support the Prevention and Control of the COVID-19 Pandemic in Africa

In 2021, Africa had a COVID-19 vaccines shortage of 470 million doses. Amid around 6 billion doses of vaccines inoculated worldwide, only 2% occurred in Africa, which not only exposed African people to the threat of diseases, but also made it possible for COVID-19 mutant strains to emerge here, jeopardizing the global anti-epidemic achievements.

For the purpose of increasing the accessibility of vaccines to assist Africa in fighting the epidemic, by the end of January 2022, Sinovac's vaccines were granted emergency use and conditional marketing authorization in 17 African countries, and around 100 million doses of inactivated COVID-19 vaccines were supplied to more than 10 African countries and regions, facilitating the prevention and control of COVID-19 in Africa.

In the meantime, Sinovac realized local production in Egypt and Algeria, and has been assisting in the construction of a fully automated cold room in Egypt.

"Sinovac will continuously deepen its comprehensive strategic cooperation with African countries in the vaccine field, encourage the diversified and all-round cooperation in terms of clinical research, local production, technology transfer and cold-chain storage, and endeavor to provide African countries with vaccines of more varieties and greater number".

——Mr. Weidong Yin, Chairman, President & CEO of Sinovac



Green Development Build Beautiful Home

Subject to the principle that "lucid waters and lush mountains are invaluable assets", ecological civilization construction is part and parcel of fulfilling the Chinese Dream of the great rejuvenation of the Chinese nation. In active pursuit of green development, Sinovac establishes comprehensive environmental management systems as well as systems for emergency management of emergent environmental incidents. It controls the total energy consumption, improves the energy efficiency, carries out cleaner production roundly, performs integrated management of waste water, waste gas and rejected materials, and strives for the harmonious development of economy and environment.

Environmental Management Framework

Sinovac has established a comprehensive environmental management framework, which not only covers various environmental management systems, but also includes the contingency plan for emergent environmental incidents and the risk assessment management system, aiming at minimizing the impact of its production and operation on the environment and surrounding communities.

Refine Environmental Management Systems

To launch orderly environmental management, the Environment, Health & Safety (EHS) Department of Sinovac shoulders the responsibility for all-round guiding, supervising and inspecting relevant events for environmental protection, regularly organizing third-party monitoring units to carry out the environmental monitoring of plants, and supervising the operation of corporate facilities for pollution prevention. The Operation Guarantee Group is responsible for operating and maintaining corporate facilities for pollution prevention, and ensuring their effective operation by means of daily inspection and regularly maintenance.

Now the Company formulates a series of systems, including the *Energy Management System, Waste Water Management System, Waste Gas Management System, Management System for Hazardous Wastes, Management System for Environmental Protection Equipment and Facilities* and *Management System for Garbage Sorting etc.,* to standardize the operation and maintenance of corporate facilities for pollution prevention, the environmental monitoring, and other work, ensuring efficient environmental management of the Company. All departments of the Company are required to collaborate with the project department for the" three-simultaneous" administration of projects (Environmental, health and safety procedures are carried out simultaneously with the project), to facilitate the handling of environmental impact assessment formalities of corporate projects and ensure the project forwarding in a compliance and orderly manner.

Through 2021, Sinovac invested more than RMB40 million in environmental protection, mainly for the update of environmental protection facility, environmental evaluation and monitoring, disposal of hazardous wastes, wastewater detection, installation and operation of online monitoring equipment, and garbage disposal.

In 2021, Sinovac Beijing obtained the ISO14001 Environmental Management System certification, which covers the production and relevant management activities of Enterovirus Type 71 Vaccine (Vero Cell), Inactivated and Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains.

At the end of 2021, Sinovac LS initiated the ISO14001 certification to make its control of various pollutants in different processes, products and activities meets due requirements.


职业健康安全管理体系认证证书

注册号: 02121S11137R0L

兹证明

北京科兴生物制品有限公司

统一社会信用代码：91110108600888085T
注册/办公地址：中国·北京市·海淀区上地西路 39 号
生产地址：中国·北京市·昌平区管通路 15 号

职业健康安全管理体系符合标准：

GB/T 45001-2020/ISO 45001:2018

认证范围如下：

肠道病毒 71 型灭活疫苗（Vero 细胞）、Sabin 株脊髓灰质炎灭活疫苗（Vero 细胞）的生产及相关管理活动

本证书有效期自 2021 年 12 月 27 日至 2024 年 12 月 26 日

认证前提涉及法律法规要求的行政许可、资质许可、强制性认证的，证书与资质类别许可有效。
在正常情况年度审核的情况下，与年度监督保持通知一并使用有效。
本证书信息可在国家认证认可监督管理委员会官方网站（www.cnca.gov.cn）上查询。

华夏认证中心有限公司
中国北京市朝阳区北辰东路 8 号汇宾大厦 B 座 211 号 邮编：100101
http://www.cvcci.com.cn

总经理：

证书专用章

证书日期：2021 年 12 月 27 日

IAF CNAS 中国认可 国际互认 管理体系 MANAGEMENT SYS CNAS C021-M


职业健康安全管理体系认证证书

注册号: U006621S0200R0L

兹证明

北京科兴生物制品有限公司

统一社会信用代码：91110108600888085T
注册/办公地址：中国·北京市·海淀区上地西路 39 号
生产地址：中国·北京市·昌平区管通路 15 号

职业健康安全管理体系符合标准：

ISO 45001:2018

认证范围如下：

肠道病毒 71 型灭活疫苗（Vero 细胞）、Sabin 株脊髓灰质炎灭活疫苗（Vero 细胞）的生产及相关管理活动

本证书有效期自 2021 年 12 月 27 日至 2024 年 12 月 26 日

认证前提涉及法律法规要求的行政许可、资质许可、强制性认证的，证书与资质类别许可有效。
在正常情况年度审核的情况下，与年度监督保持通知一并使用有效。
本证书信息可在国家认证认可监督管理委员会官方网站（www.cnca.gov.cn）上查询。

华夏认证中心有限公司
中国北京市朝阳区北辰东路 8 号汇宾大厦 B 座 211 号 邮编：100101
http://www.cvcci.com.cn

总经理：

证书专用章

证书日期：2021 年 12 月 27 日

IAF UKAS MANAGEMENT SYSTEMS 0066

Develop the Contingency Plan for Emergent Environmental Incidents and the Risk Assessment Management System

To reinforce the prevention management of emergent environmental incidents, standardize emergency management, improve the capability of dealing with risks and preventing accidents, avoid or minimize personnel casualties, and lower environmental impact, Sinovac, subject to the principle of" comprehensive coordination, classification management and graded responsibility" , formulates the *Contingency Plan for Emergent Environmental Incidents* with a view to strictly implementing the risk assessment management and managing environmental events effectively.

Response Procedure of Sinovac LS to Emergent Environmental Incidents

To achieve the timely response to and standard management of emergent environmental incidents, Sinovac LS formulates the *Contingency Plan for Emergent Environmental Incidents* in light of its actual production and operation situation with a view to clarifying the operation and response mechanism.

Command and Operation Mechanism

The Company has sets up the emergency organization and command system for emergent environmental incidents, with the general manager of the Company as the general commander, consisting of the Emergency Headquarters, On-site Disposal Group, Environmental Emergency Monitoring Group, Emergency Support Group and Emergency Information Contact Group.

Graded Response

In accordance with the hazard rating and influence sphere of incidents as well as the Company's capability of controlling the situation, the Company adopts the two-level emergency response mechanism that classifies potentially emergent environmental incidents into social-level ones and enterprise-level ones.





Figure 2-2: Procedure Chart of the Emergency Response to Emergent Environmental Incidents

Make Aggressive Efforts for Energy Conservation and Emission Reduction

Sinovac attaches great significance to the issue of climate change. From project approval and design to post-operation and management, the Company upholds the concept of "energy conservation and emission reduction" for the purpose of controlling the total energy consumption, enhancing the energy efficiency, and contributing to realizing the goal of "peak carbon dioxide emissions and carbon neutrality".

In 2021, Sinovac LS established the energy-saving management leading group to conclude decisions on energy management. The energy management is subject to three-level management mechanism of company, department and shift, where the head of each department/shift serves as the person in charge of energy management in the graded management mechanism and assigns part-time energy administrators separately in light of the need to form the company-level energy management network. To realize the standard energy management, and encourage the departments and employees to actively practice the concept of energy conservation and emission reduction, Sinovac LS also formulates the *Energy Management System* to achieve the standard management of the use, measurement, statistical report and consumption cost of electricity, fuel, natural gas and heating power etc., and develops the internal *Reward and Punishment Ordinance* to grant commendation and rewards to departments and individuals excelling in energy conservation.

Comprehensive Energy Consumption Per Unit Output Value



Fully Carry out Cleaner Production

Sinovac adheres to cleaner production, and reduces pollutant emission by optimizing facilities for pollution prevention and treatment, which fundamentally tackles environmental pollution and ecological damage. Through 2021, Sinovac strictly complied with applicable laws and regulations, and timely completed the handling of pollutant discharging permits. Furthermore, the Company also worked out a monitoring plan targeting waste water, noise and waste gas, and engaged qualified third-party inspection institutions to take samples on site for inspection and to issue the formal inspection report, thus ensuring its indexes meet due emission standards.

The hazardous wastes generated from vaccine manufacturing mainly include waste chemical reagents, abandoned vaccines, pharmaceutical wastes, high-risk workshop wastes and contaminated wastes. To ensure the effective identification and management of wastes, especially hazardous wastes, in 2021, the Company updated the *Reference List of Hazardous Waste and the Management System for Hazardous Wastes* in accordance with relevant latest official documents including *National Hazardous Waste List (2021 Edition), Identification Standards for Hazardous Wastes – General Specifications* and *Reply to the Opinions on Disposal of Solid Wastes Generated by Inactivated COVID-19 Vaccine Manufacturers*, and carried out strict management of and imposed demanding requirements for the packaging, collection, storage, transfer and disposal etc. of hazardous wastes.

To ensure the compliance of temporary storage and disposal of hazardous wastes, all companies of Sinovac are outfitted with temporary storage rooms of hazardous wastes, and prevent hazardous wastes from loss and leakage by means of sorting and partition of goods, registration of inflow and outflow, strict packaging and other measures. All hazardous wastes are disposed of by eligible professional third parties in strict accordance with the national harzardous waste transfer procedures.

In 2021, the Company fully satisfied the discharge standards of waste water and waste gas, and pollutants. Hazardous wastes are disposed in strict accordance with the regulatory requirements, and no excessive pollution was found throughout the year.

Table of Pollution Prevention and Treatment Measures

Type	Description	Procedure and Measures of Disposal
Waste water	**Production wastewater** It refers to the waste water generated by bulk workshops, preparation workshops and quality control labs etc. during the process of manufacturing or quality inspection	Poisonous wastewater with biological activity generated by bulk workshops shall be initially disposed of through targeted disposal system to meet the standard, and then channeled into the wastewater treatment station of the factory together with other non-toxic wastewater generated by bulk workshops, preparation workshops and quality control labs for disposal, which, after reaching due standards, will be discharged into a recycled water plant or a wastewater treatment plant through municipal pipeline network for further disposal
	Domestic wastewater It refers to the waste water produced by employees in office and life, mainly including water for personal hygiene and toilet water	Domestic sewage shall be discharged into a recycled water plant or a sewage treatment plant after being treated by the septic tank through municipal pipeline network
	Clean wastewater It refers to the waste water generated from the softened water system, pure water system, water for injection system, pure steam preparation system and circulating cooling water system	The waste water generated from softened water system, pure water system, water for injection system, pure steam preparation system and circulating cooling water system shall be directly discharged into a recycled water plant or a wastewater treatment plant through municipal pipeline network for disposal
Waste gas	Clean waste gas likely to generate biological activity	It shall be initially disposed of through the waste gas treatment system in conformity with biosafety requirements, and discharged after reaching due standards
	Production waste gas	It shall be initially disposed of through discharge pipeline and corresponding treatment facilities of each production workshop, and discharged after reaching due standards
	Waste gas from wastewater treatment stations	It shall be initially disposed of through discharge pipeline and waste gas treatment facilities, and discharged after reaching due standards
	Waste gas generated by boilers	It shall be initially disposed of through low nitrogen burner and discharged after reaching due standards
Solid wastes	**Household waste** It includes kitchen waste, recyclable materials, hazardous waste and bulky waste etc	Kitchen wastes have been separated from other wastes from generation, and shall be free of glass, ceramic, metal debris, plastics and rubber; Recyclable materials shall be kept clean, dry and free of contamination on classification and throwing; Hazardous waste shall be kept complete on throwing to avoid secondary pollution; Bulky wastes shall be thrown to the recovery zone of bulky waste. Resourceful on-site processing is encouraged if due conditions are met; otherwise, make an appointment with eligible third parties for door-to-door recovery.
	Construction waste It refers to muck, concrete blocks, crushed stone, brick and tile fragments, waste mortar, mud, asphalt blocks, scrap metal and waste wood and bamboo	Most construction waste falls into the scope of recyclables. In addition, construction and decoration wastes may contain hazardous substance, for which they shall be thrown and disposed of as per the concrete classification
Noise	It refers to the sound generated by various electromechanical devices on operation	Isolate source of noise from working personnel as much as possible, give priority to equipment with lower noise, minimize the running time of various electromechanical devices, carry out regular maintenance for the equipment, reinforce the routine inspection of various electromechanical devices, install silencers for equipment with greater noise, regularly inspect whether silencers work, and install acoustic panels and other facilities available in equipment rooms with greater noise to control noise transmission

Administration of Sinovac LS on Waste Gas Emission

Given the specialty of vaccines, the manufacturing environment of vaccines bears extremely demanding requirements for cleanliness. To keep favorable manufacturing environment of vaccines and ensure vaccine quality, Daxing production site of Sinovac LS need disinfect the surface of the equipment and the ground of the working place regularly with disinfectors that comprises ethyl alcohol, compound alcohol, alkaline phenol and other substances, and inevitably generate certain amount of non-methane hydrocarbon. In addition to minimizing the use of disinfectors, to ensure the compliance of waste gas emission, Sinovac LS applied the active carbon absorption equipment for relevant exhaust vent of workshops during the construction process, for which the absorption efficiency of organic waste gas exceeds 80% and the waste gas of workshops is discharged in a compliance manner.

To prevent ethyl alcohol, isopropanol, formaldehyde solution and other organic solvents contained in hazardous wastes from accidental leakage or volatilization during the process of temporary storage, in the meantime, the production sites are outfitted with exclusive areas for the temporary storage of hazardous waste, and has the active carbon absorption equipment installed to avoid adverse impact of hazardous wastes' accidental leakage to the atmosphere.

To avoid the atmospheric pollution resulting from sulfuretted hydrogen, ammonia and other waste gas generated from the disposal of waste water in the tank of wastewater treatment station, the tank of wastewater treatment station is fully enclosed, and waste gas generated from the tank is initially collected by the exhaust fan in an uniform fashion, then disposed of through two-level active carbon absorption equipment, and eventually discharged after reaching due standards, for which the comprehensive management of volatile organic compound is realized.

Compliance Disposal of Waste Water by Sinovac LS

Vaccine manufacturing includes the use of bacteria and viruses. To achieve the effective and compliance disposal of production wastewater and the compliance and safe disposal of poisonous wastewater with biological activity, all companies of Sinovac have constructed exclusive biological wastewater treatment system and wastewater treatment station.

The biological wastewater generated from production workshops and R&D workshops mainly includes virus culture medium and washing liquid, which shall be inactivated and pretreated by the biological wastewater treatment system that adopts the heating method of industrial stream and keeps wastewater at high temperature for a certain time to achieve the inactivation effect.

After wastewater is confirmed without biological activity, all production wastewater flows into the wastewater treatment station through wastewater pipelines in the production site. To ensure the discharge meets the standards, the relevant pollution indicators are reduced by adopting the process of "grating + regulating reservoir + anaerobic tank + hydrolytic acidification + aerobic tank + sedimentation tank + sodium hypochlorite disinfection".

Compliance Disposal of Waste by Sinovac Dalian

To ensure the compliance disposal of waste, Sinovac Dalian entrusts professional third-party companies to dispose its waste.

In combination with various requirements for the destruction and supervision of different waste, the Company works out corresponding strategies for destruction and supervision. Based on the demands of each business department, the Company contacts the destruction units, and integrates field supervision with video recording etc. to ensure the efficient and closed-loop management of the whole destruction process.



Low Nitrogen Burner of Sinovac LS

The standby boilers constructed by Sinovac LS are used within the annual maintenance period of municipal gas supply. To realize low emission concentration of waste gas generated from such boilers and ensure the compliance with emission indicators, all boilers of the Company are new low nitrogen burners.

Compared with conventional burners, low nitrogen burners see the addition of blast blowers, induced draft fans, transducer valves and integration of multiple circuits, achieve the combined action of clean energy and burner operation, and provides boilers with more efficient thermal conversion.

Water Resource Management

To realize the effective management of water resources, Sinovac formulates the *Responsibility and Appraisal System for Water-saving Targets, Management System for Water-using Equipment, System for Water-saving Promotion* and other management systems. For the strict implementation of various water-saving management systems, the Company has set up the Water-saving Office to continuously standardize water-using behaviors in accordance with relevant systems, reduce waste of water resources, and lead employees to carry out water-saving actions consciously.

To enhance the water-saving awareness within the Company, the Water-saving Office proactively organizes employees to participate in water-saving lectures and meetings, and endeavors to improve the water-saving management level across the Company by encouraging employees to study relevant laws and regulations and water-saving brochures. In the meantime, Sinovac proactively creates favorable water-saving climate within the Company, and reinforced employees' awareness of loving, protecting and saving water by putting up water-saving posters and hanging water-saving banners in public areas, and pasting water-saving slogans in toilets and canteens and other main places of water use.

Comprehensive water consumption per unit output value

0.16 Ton/RMB10[4]

Sinovac's Disposal of Domestic Sewage

Aside from workshops for vaccine production, R&D and quality control, each production site of Sinovac also includes offices, accommodation and canteens etc. In this connection, wastewater generated in these places are classified into industrial wastewater and domestic wastewater, among which domestic wastewater may be discharged out of each production site through pipelines after the degradation at the septic tanks. To further reduce the discharge indexes including Chemical Oxygen Demand (COD), BOD5, animal and vegetable oils, nitrogen oxide and number of fecal coliforms and other indicators, the domestic wastewater is further treated at the wastewater treatment station to further cut down the discharge concentration of the foregoing pollutants.

The treatment capacity of each wastewater treatment plant can fully satisfy the treatment demands for domestic sewage. By adding more sewage conduits, the index of domestic sewage is further reduced, which plays a positive role in protecting the surrounding water environment.



Wastewater Treatment Station of Sinovac Dalian

Green Logistics and Warehousing

Transportation and logistics are major channels of greenhouse gas emission. In this connection, Sinovac lays emphasis on the green and low-carbon logistics, and create the green and smart logistics system and green warehousing and perform delicacy management of the energy consumption of cold room by optimizing the transportation procedure.

Green Logistics

In 2021, the Company mainly adopted the pattern of "dominated by less-than-truckload (LTL) freight and supplemented with car rental". The Company achieved the centralized transportation to cold room in different cities by means of allocation, forms the transportation scale effect, and developed the integrated distribution mode of "regional warehousing and regional distribution" in each province, for which it was able to integrate transportation and distribution in accordance with the time-based demands of customers, and optimize the transportation routes.

Green and Intelligent Logistics Ensures Higher Distribution Efficiency

To achieve energy conservation and emission reduction during the transportation process, the Company entrusts professional third-party pharmaceutical cold chain logistics enterprises with GSP qualification to carry out door-to-door transportation and distribution of its products, and authorizes distribution enterprises to apply exclusive systems as transportation management system and cold chain temperature monitoring system for the purpose of realizing the binding of transportation orders with vehicles, vehicle scheduling, real-time feedback and inquiry of the location and temperature during the transportation process, sound alert with light effects and message alert against abnormal temperature, and real-time printing and other functions. In the meantime, the Company opens to its customers the distribution information platform, where customers may check the distribution location of refrigerated trucks without delay to realize the accurate arrangement for receiving delivery and allocation. On the one hand, the effectiveness for vaccine transit may be remarkably facilitated to reduce the waiting time for vaccination. On the other hand, the timeliness and efficiency of transportation is enhanced to shorten the idling time of the refrigerated trucks and reduce the exhaust emission.

Green Warehousing

There are explicit requirements for the green construction and modification of logistics and warehousing places under the Green Industry Guidance Directory issued by the government. All companies of Sinovac proactively respond to national policies and continuously enhance the construction of green warehousing system.

The Company imposes strict control over the energy consumption in all links of material storage. In light of the characteristic requirements for material storage conditions, the Company classifies the refrigerating chambers into freezer warehouse with a temperature below -15°C , 2°C -8°C refrigerated warehouse, and normal temperature warehouse. The normal temperature warehouse is further divided into cool storage room with a temperature of no more than 20°C , 10°C -30°C warehouse and normal warehouse without controlled temperature in accordance with different temperature requirements. Thanks to the refined partition of material warehouses by temperature, it is possible to avoid setting the temperature in the general temperature range for all the warehouses, minimize the repeated start of central air-conditioning in a large space, and markedly reduce the power consumption. In the meantime, hand-actuated liquid forklifts and hand-actuated hydraulic pushers etc. are used within the final bulk cold room of Sinovac Dalian for loading, unloading and transfer with a view to avoiding energy consumption and exhaust gas emission.

Furthermore, the Company encourages the application of reusable packaging within warehouses, and substitutes cold chain transport cases and pass boxes of different packaging materials with reusable packaging for the purpose of reducing resource consumption and waste.

Routine Inspection of Material Storage Warehouse and Cold Room by Sinovac LS

Sinovac LS carries out irregular inspection of materials storaged in Material stored Room, and adjusts the temperature control range thereof from time to time in light of the material characteristics. In 2021, when inspecting the Material Storage Warehouse V where raw materials and excipients were stored, the Company timely changed the temperature range of this room to 16°C -29°C after spotting that the raw materials and ingredients with a demand of the temperature range of 18°C -25°C were removed from here, and correspondingly adjusted the temperature of Material Storage Warehouse I where such raw materials and excipients were subsequently placed.

The gross area of Material Storage Warehouse V and Material Storage Warehouse I is 415 square meters. Upon adjustment, the working time of central air-conditioning declines by 3 hours daily on average. If calculated as per the standard that one air conditioner is required per 10 square meters and 1 kilowatt is consumed by each air conditioner per hour on average, it is possible to save 126 kilowatts every day.

Heartwarming Workplace Grow with Employees

Sinovac safeguards the basic rights and interests of employees by virtue of standard systems, enables employees to embrace growth by launching diversified training, and allows employees to demonstrate their talents through abundant recreational and sports activities. Now ongoing efforts are made by Sinovac to empower employees to carry out their roles, such as launching an equal, diversified and secure working environment, enhance the sense of achievement and happiness of employees, and enable them to grow together with the Company.



Protection of Employees' Rights and Interests

Sinovac strictly observes domestic laws and regulations as well as international conventions pertaining to labor and human rights, fully implements relevant policies for equal and non-discriminatory employment, and provides comprehensive salary and welfare systems for the purpose of protecting the legitimate rights and interests of employees, creating a fair, inclusive and harmonious working environment and seeking for common growth with employees.

Employment Policies

Sinovac undertakes to sign an employment contract with its employees and build a harmonious labor relation with them in strict accordance with *Labor Law of the People's Republic of China, Labor Contract Law of the People's Republic of China, Social Insurance Law of the People's Republic of China, Labor Dispute Mediation and Arbitration Law, Regulation on Wage Payment, Regulation on Work-related Injury Insurances, Special Rules on the Labor Protection of Female Employees, Measures for the Determination of Work-related Injuries* and Law of the People's Republic of China on the Protection of Women's Rights and Interests and other applicable laws, regulations and systems.

Salary and Welfare

To fuel the work enthusiasm of employees and standardize the salary management, Sinovac formulates a fair and reasonable salary system. The salary of each employee is determined upon comprehensive consideration of diversified elements, such as general wage level of similar enterprises in the society and their ability to pay, general price level, duties and title, educational background, workplace competencies, experience, years of service and performance of the employee. For employees exposed to special working conditions, the Company develops the allowance system correspondingly and provides them with extra compensation in response to their work. In addition to paying the competitive salary, the Company also pays social insurance premiums for employees in full as per the *Social Insurance Law*, and takes out supplementary medical insurance for them.

Communication with Employees

Sinovac, paying great attention to employees' feelings and voices, develops an effective management and communication mechanism. Furthermore, Sinovac has established the grassroots labor union, fully implemented laws and regulations, including Trade Union Law, Labor Law and Labor Contract Law and other applicable laws and regulations, and established sound democratic management procedures and systems as well as improved the organization chart of the labor union, aiming at building stable and harmonious labor relations, and safeguarding the legitimate rights and interests of employees. Upholding the work concept of people foremost and humanistic care, the labor union endeavors to enhance the sense of ownership of employees, and mobilizes and organizes employees to participate in the democratic management of the Company. Currently, the labor union is actively preparing for the workers' congress, perfecting the democratic management of the Company, and realizing the "win-win result for the labor and the capital by seeking common development".

The labor union has established channels for rational suggestions in forms of email, suggestion box, telephone and interview to collect suggestions from employees, and mobilize and organize employees to contribute ideas to corporate operation and development. Furthermore, the in-depth communication and dialogue mechanism between leaders and employees and among employees was developed to achieve the harmony and unity between individual value and enterprise spirit through open, equal and sincere communication. In addition, the Company, by holding regular general manager dialogues and breakfast meetings, provides opportunities for face-to-face communication between senior management and employees, to enable grass-roots employees to directly reflect daily concerns and gain more understanding of the Company's development trend, making employees feel more involved in corporate development and reinforcing the cohesiveness of the Company. In addition, in response to the appeals of employees, the Company carries out a series of corporate culture activities with a view to reinforcing the team cohesiveness, lifting employees' pressure, and caring their physical and psychological health. In the meantime, the Company also carries out onboarding training, surveys on employee engagement and satisfaction with canteens and shuttle buses etc. to timely understand employees' thoughts, earnestly resolve problems confronting employees, and formed systematic and complete channels for suggestion and feedback.

Diversity of Employees and Equality of Opportunities

Subject to the principle of equal employee management, Sinovac treats all the employees in a equitable and impartial manner, rather than restrict the development of any employee due to gender, nationality, race, disability or other elements. The salary of an employee is determined as per the Company's salary system and his/her ability. Employees enjoy equal payment for equal work regardless of gender. In the aspect of talent selection and promotion, the Company channels more resources into the promotion of internal talents and provides equal opportunities for talent development while intensifying talent employment.

Proportion of female employees
42 %

Proportion of minority employees
9 %

Employment rate of the disabled
1 %

Occupational Health and Safety of Employees

In accordance with the *Code of Occupational Disease Prevention of the People's Republic of China, the Classified Catalogue of Occupational Diseases* and other applicable laws and regulations, Sinovac identifies the present occupational hazard factors and posts exposed to occupational hazard factors in combination with the characteristics of its present posts, develops the *Summary Sheet of Posts Exposed to Occupational Hazard Factors,* and improves and practices the *System for Occupational Health Monitoring and Archive Management* to guard the vital interests of employees. Directed by the people-oriented operation principle, the Company ensures the occupational safety of employees, and minimizes the risks of occupational diseases from two aspects, namely, production safety and occupational health.

Occupational Health Monitoring and Management

Sinovac proactively practices the System for Occupational Health Monitoring and Archive Management, performs occupational health monitoring for newly-hired, on-duty and off-duty personnel of the Company who are/were exposed to occupational hazard, and notifies them of the written results of the check-ups. To enhance the management on occupational health protection, Sinovac outfits corresponding occupational protection articles for each post in light of the System for Labor Protection Article Management for the purpose of safeguarding the occupational health of employees.

In accordance with the Specifications for Notification of Occupational Hazard by Employers and Warning Signs issued by the State Administration of Work Safety, Sinovac develops the Management System for Occupational Hazard Warning and Notification, and sets corresponding warning signs as required in the workplace, operating posts, equipment, material (product) packaging and storage locations where generate or suffer occupational hazard factors, such as" Hazardous Noise" and" Wear Ear Protectors" setting for posts of visual inspection and packaging at the COVID-19 production workshops.

2021 Occupational Health Management Performance of All Companies of Sinovac

Number of people suffering occupational diseases
0 Person

Coverage rate of check-ups and health archives
100 %

Total times of occupational health and safety training
64 Times

Occupational Health and Safety Training Launched by Sinovac Beijing for Employees Through the Year

To reinforce the occupational health awareness of the personnel, and popularize applicable laws and regulations pertaining to occupational health, in 2021, Sinovac Beijing organized 64 occupational health and safety trainings as well as 30 drills online and offline targeting laborers exposed to occupational hazard, occupational health managers and principals with an aggregate number of 4,731.

Production Safety Management

With respect to the production safety management, Sinovac sorts out its internal systems in accordance with applicable laws and regulations, completes the standardized document system for safety production, and reinforces the daily safety inspection to make the safety management more standardized. To enhance the safety awareness of relevant personnel, Sinovac increases its safety publicity efforts, regularly organizes safety training and emergency drills within the Company, including training on safety, health and fire protection targeting all the staff and training for special personnel, and resorts to cooperation to improve the overall safety production management capability of the Company.

2021 Safety Performance of All Companies of Sinovac

Input in safety training
162.39 RMB10[4]

Input in safety production
3,138.07 RMB10[4]

Times of safety training
81 Times

Coverage rate of safety training
100 %

Times of safety emergency drills
39 Times

Major safety accidents
0 Accident

Injury frequency
0 Number of employees injured / million working hours

Working Arrangement of Sinovac Dalian for Routine Safety Inspection

To safeguard employee's health and production safety, Sinovac Dalian establishes orderly safety inspection systems and norms, according to which it carries out routine safety inspection every day, safety inspection of hazardous goods warehouses every week, and troubleshooting of potential safety hazards throughout the factory every month, as well as well-targeted and regular special inspection and comprehensive safety inspection before holidays and festivals, all for the purpose of timely spotting and eliminating potential safety hazards existing in routine production.

As to the construction site, Sinovac Dalian performs at least 4 routine safety inspections every day, and forms the written records of inspection results. By collaborating with internal and external institutions to inspect potential safety hazards at the construction site, the Company comes up with its suggestions for rectification mainly on the potential safety hazards in fire protection, approach to the edge, scaffold on external walls and construction equipment, and traced the implementation of such rectification.

Safety Education and Training Provided by External Experts at Sinovac LS

In May and December 2021, Sinovac LS hired the hazardous chemicals experts to carry out special training for two times, invited all the personnel along the whole chain of hazardous chemicals to attend training, and popularized to relevant personnel key requirements for urban work pertaining to hazardous chemicals, laws and regulations concerning hazardous chemicals, cases of accidents with hazardous chemicals involved and emergency response to the leakage of hazardous chemicals, with 101 personnel of relevant posts covered accumulatively.

Employee Growth and Development

Corporate development and the individual growth and development keep pace with each other. In this connection, Sinovac is willing to render vigorous support to the development of each member of Sinovac, combining talent cultivation with incentive. The Company introduces talent cultivation programs at the company level, develops reasonable training systems upon consideration of the actual demands of employees, strengthens internal talent promotion, implements talent development work, encourages employees to pursue diversified career development, and continuously enhances the sense of accomplishment of employees by providing them with various growth opportunities and empower them to carry out their roles.

Talent Introduction

Underpinned by its complete recruitment systems, Sinovac increases external talent recruitment and introduces more key external talents, and reserve internal high-quality talents for the development of the Company by strengthening the talent promotion, ensuring the talent supply, and improving the talent risk management.

Campus Recruitment

Campus recruitment plays a significant role in helping enterprise absorb and reserve high-quality talents. As for Sinovac, it provides employment opportunities for college students by directly facing the college students through school-enterprise cooperation, convening campus lectures and organizing college students to visit its factories.

Campus Recruitment of Sinovac Themed by "Work together to prosper Sinovac"

In August 2021, with Sinovac as the main body, Sinovac Beijing, Sinovac LS and Sinovac Dalian jointly convened the campus recruitment, themed by "Work together to prosper Sinovac", organized 9 career talks at universities, including Peking University and Tsinghua University, and eventually provided more than 80 employment opportunities for over 3,800 candidates who submitted their resumes.



Talent Cultivation

Sinovac unceasingly improves its talent quality and competence, plans the talent cultivation system, and developed the knowledge and personnel management system with Sinovac's characteristics by "evaluating, stimulating and cultivating people". While further enlarging the range of people covered by the training, Sinovac launches more detailed and targeted training for highly potential talents to ensure overall quality improvement of the personnel and encourage the individual growth of some employees. In 2021, the training coverage rate of Sinovac LS reached 100%.

Was rated
Top 10 China Most Aspiring Employers in Beijing
China Best Employer Award 2020*

Sinovac Academy – Elite Training Plan for Fresh Graduates

In 2019, Sinovac initiated the "Elite Training Plan for Fresh Graduates" to help fresh graduates transit from students to employees, enable them to gain more understanding of Sinovac rapidly, and enhance their sense of identity and belonging.

Based on Sinovac Academy, Elite Plan provides fresh graduates with one-year proposal for systematic integration and cultivation, and contributes to corporate business through cultivation and development of key talents. Elite Training Plan represents a new exploration of Sinovac in retaining and motivating talented fresh graduates, which remarkably facilitates the construction of its back-up talent echelon.

In 2021, Sinovac upgraded the Elite Training Plan, summarized and extracted previous experience, explored the fresh students' learning and development trajectory, and added the training by professional mentors to further improve the fresh graduate cultivation and development system and enable fresh graduates to integrate with Sinovac as soon as possible.

*The selection of "China's Best Employer" is jointly organized by the Peking University Social Research Center, the National School of Development of Peking University, the China Association of Labor Economics, Harvard Business Review, Zhaopin, etc., and has received support from international institutions, such as UN Women and WHO. The event was launched in 2005 and is the most authoritative and credible brand list in the domestic human resources field.

Mentors Are "Torch Carriers" of Fresh Graduates

Elite Training Plan covers near 20 departments in four major systems, targets fresh graduates with bachelor, master and doctoral degrees, and includes 26 returnees who studied abroad. It is important to realize the cross-department, cross-business system and cross-educational background interactive study and exchange among employees, and enable them to embrace ongoing growth within the Company by managing selected trainees by class, keeping the training led by the mentor team as the core, having the head teacher team concerning the growth of selected trainees in each class, and authorizing the HR team to organize and operate this elite training program.

The program lasts for nearly 2 months, and is subject to the mode of "combining study with practice". Upon the end of relevant courses, lecturers provide one-to-one tutoring and feedback based on the practical performance of each trainee, present further tutoring and explanation for common and representative problems confronting trainees in a unified manner, and generate the manual instruction of mentors, providing new thoughts and methods for managers to perform daily personnel management.

Through 2021, the Elite Training Plan got 611 trainees and 237 mentors involved.





Training for New Employees

New employees represent the future of the Company, for which the integration and cultivation of new employees is part and parcel of Sinovac's human resources management. By virtue of Sinovac Academy, Sinovac unceasingly launches training for new employees and helps them integrate with the Company.

Sinovac Academy Enables New Employees to Step up the Integration with the Company

Through 2021, Sinovac Academy launched 30 trainings for new employees with 2,794 people covered and the training satisfaction up to 98%. Aside from conventional training for new employees, it also provided special trainings on marketing and international business, as well as trainings that aligned with different business systems, in a bid to make training more systematic and well-targeted.

Training by Internal Lecturers

Based on their own characteristics and needs, Sinovac launches internal lecturer trainings for the purpose of inheriting their excellent skills and management experience and enhancing the vocational skills of new employees and the capability of managers.

Cultivation of Internal Trainers by Sinovac Beijing

Sinovac Beijing builds the knowledge dissemination platform for internal trainers by virtue of Sinovac Academy, and connects that with Sinovac Group's lecturer cultivation program. In 2021, the training program of internal trainers launched by Sinovac Beijing saw the recruitment of 25 employees, and delivered training to potential personnel by sorting out the logic and content of the course presentations and explaining teaching skills. Eventually, 10 employees were certified as internal trainers and created 15 standard course presentations.



Care for Employees

In addition to providing employees with competitive salary and welfare and diversified growth opportunities, Sinovac pays due attention to the sound physical and mental development of employees, and carries out a number of employee-caring activities to reinforce their sense of belonging and cohesiveness to enable them to embrace a pleasant job and a happy life.

Varieties of Employee Activities

In response to different festivals, major dates for the Company's business and birthday of employees, Sinovac regularly organizes thematic or cultural and sports-related activities, and unveils innovative activities through elaborately designed ceremonies, so as to create a harmonious, warm and joyful atmosphere within the Company. In addition, the labor union opens to employees extensive welfare channels, and successively provides diversified recreational sites and activities to enhance their sense of identity and contribute to enterprise development. Affected by the COVID-19 pandemic, a number of employees of Sinovac failed to return to their hometowns to reunite with their families during the Spring Festival of 2021. The Company prepared diversified New Year's Eve activities and pool them together to celebrate the Spring Festival.

5th "Benefit Future" Family Carnival Activity

As of 2017, the Company has organized the "Benefit Future" Family Carnival Activity for 5 consecutive years, inviting near 300 children of members of Sinovac as well as some external guests' children and their parents to gather at the parent-child carnival to make members of Sinovac feel the Company's concern for their families.



"20 Benefits Sinovac" Celebration for the 20th Anniversary of Sinovac

As 2021 encountered the 20th anniversary of Sinovac, the "20 Benefit Sinovac" celebration was carried out. Sinovac reviews the original intention of entrepreneurship, highlights its mission, confers medals to employees with 5/10/20 years of service respectively to motivates other employees, collects and shoots vides of major events over the past 20 years, and demonstrates the beautiful figures of members of Sinovac.



Diversified Employee Activities Organized by the Labor Union



Basketball Game



Table Tennis Match



Mid-Autumn Festival Activity



Spring Festival Activity

Care for Employees' Life

Through 2021, Sinovac convened a series of trainings, lectures and thematic activities to care the physical and mental health of employees. For female employees, the Company provides special care by outfitting baby care rooms and offering maternity leave. To celebrate the 2021 International Working Women's Day (March 8), Sinovac organized the training on beauty and skin care knowledge for female employees, and delivered the "International Working Women's Day" gifts to them. For employees in financial difficulties, the Company gets their situation timely and gives them condolences. Adhering to the principle of enabling employees to embrace "a pleasant job" and "a happy life", the labor union continuously improves the construction of various life and leisure areas upon consideration of employees' demands, including psychological counseling room, mediation room for labor relations, library, multimedia projection room and tea room, so as to create a favorable and sound work environment for employees.

Lecture on "Common Psychological Problems in the Workplace"

In September 2021, Sinovac Beijing invited a psychological consultant to organize the lecture on "Common Psychological Problems in the Workplace" where the psychological consultant offered case-based analysis on the status quo, types and clinical manifestation and other aspects of common psychological problems in the workplace to help employees learn some common sense of mental health.

Thematic Activity of Physical Health of Employees: "Healthy Sinovac, Fight against Obesity"

To ensure due attention are paid to health issues such as overweight and obesity and other health problems from overwork, in November 2021, Sinovac Beijing initiated the "Healthy Sinovac, Fight against Obesity" for one month, which got more than 400 employees involved and helped 201 persons lose weight successfully, with the total weight loss of 397.4kg.



Library



Staff Activity Center

Benefit the Society
Achieve Common Prosperity

As a responsible biological high-tech enterprise, Sinovac insists on benefiting the society with its development achievements, and supporting the development of community-based public health and medical services while continuing its R&D and spreading of vaccines and services and contributing to the disease prevention and control.



Deliver Health and Wellbeing by Fulfilling Public Responsibility

In addition to repaying the country and the society and safeguarding people's health with high-quality vaccines, Sinovac proactively fulfill its social responsibility, fuel scientific research and health science popularization in the biopharmaceutical field, In addition, Sinovac carries out various donations, including vaccines, to facilitate the development of public health through practical actions, and cooperates with others from all sectors to jointly build a healthier world. Since its inception, Sinovac Beijing, Sinovac LS and Sinovac Dalian have accumulatively donated vaccines, supplies and aid in construction etc. valued more than RMB8 billion in total to the public health undertaking and the society.

Proactively Carry Out the Donation of Vaccines and Supplies

To support the domestic fight against the COVID-19 pandemic, Sinovac proactively carried out the donation of COVID-19 vaccines and relevant supplies. By the end of 2021, Sinovac had donated more than 300 million doses of COVID-19 vaccines free of charge to all the provinces of China, freely provided the health systems in 28 provinces, 183 prefecture-level cities and 462 districts/counties with supplies for epidemic prevention and elimination or construction assistance, and furnished the logistics support for mass vaccination. Specifically, Sinovac, in light of the actual work and living needs of the personnel at the forefront of epidemic prevention in different areas, donated nearly RMB1 million for purchasing office supplies including laptops, desktop computers, printers, scanners, as well as daily supplies such as wireless fans and motorcycle helmets, for the purpose of supporting and improving the work environment and conditions of the personnel at the forefront of epidemic prevention.

To live up to the Chinese commitment of "making the COVID-19 vaccine a global public product" and bridge the global "immunization gap", Sinovac has proactively donated vaccines to overseas countries, especially to less developed countries and regions, and assisted them in constructing cold room and other supporting facilities.







Safeguard the Health of the Next Generation by Donating Mumps Vaccines

Mumps is an acute infectious disease resulting from mumps virus that may invade testicles, ovaries and central nervous system, etc., and further lead to significant complication. The disease occurs throughout the year, with peak incidence in winter and spring. Populations not yet vaccinated with mumps vaccine are particularly susceptible to mumps, and mumps features higher incidence in children and adolescent. Collective institutions, such as kindergartens, schools and other densely populated areas, are more likely to experience the outbreaks of mumps.

In recent years, Health Commission of Shaanxi Province has included mumps into the top ten infectious diseases deserving key prevention and control in Shaanxi Province. An the priority is given to the vaccination of primary and secondary school students with vaccines included mumps for the purpose of preventing the prevalence and outbreak of mumps in schools.

Since 2020, Sinovac has donated live attenuated mumps vaccines to Shaanxi Provincial Center for Disease Control and Prevention through Shaanxi Charity Association for 2 consecutive years, in a bid to fully support the health authorities of Shaanxi Province in carrying out free supplementary vaccination of secondary school freshmen with mumps vaccines, improve the status of low inoculation rate of mumps vaccine and weak immunologic barrier among people of this age group prior to the inclusion of mumps vaccine into the immunization program, enhance the immunity of those adolescents against mumps virus, and facilitate the prevention and control of mumps in Shaanxi Province.

In 2021, Sinovac Dalian donated 60,000 doses of live attenuated mumps vaccines to Shaanxi Provincial Center for Disease Control and Prevention in total with the aggregate value of RMB2.64 million.



Earnestly Fulfill Social Responsibility by Establishing Sinovac Foundation

Sinovac Foundation was officially registered in Beijing Municipal Bureau of Civil Affairs on February 14, 2022 to carry forward the philosophy for public benefit and practice the mission of public welfare. Sinovac LS, Sinovac Beijing and Sinovac Dalian jointly donated RMB20 million to the Foundation. In the future, Sinovac Foundation will enhance the development of the cause of public good by funding scientific research and innovation as well as academic exchange and talent cultivation in the biopharmaceutical field, funding aid for the harm caused by natural disasters, accidents, public health events and other emergency events.

Safeguard the Public Health through Health Science Popularization

Apart from safeguarding health and repaying the society with high-quality vaccines, Sinovac also explores and innovates the science popularization content catering to the public demands, utilizes new media platforms for promotion, spreads and shares professional knowledge in multiple channels with full coverage, and enhance public awareness of vaccination and the importance of vaccines for disease prevention to further lift the inoculation rate, lowers the incidence of diseases, and let the idea that vaccines protect them from diseases take root in people's minds.

In the meantime, Sinovac proactively cooperate with disease control and prevention units to regularly preach vaccine-related knowledge to professional personnel and the public on public open day, field lectures or parent class, or by online information push and information dissemination and many other ways, and developed a vaccine science popularization base. By virtue of multi-cooperation, the Company carries out diversified activities to popularize scientific knowledge among the masses, including science popularization that vaccines may prevent diseases, publicity of knowledge concerning epidemic diseases and infectious diseases, and public benefit activities targeting focus groups/special groups.

Through 2021, Sinovac carried out 3 large-scale public benefit activities for science popularization, and issued 222 medical science popularization articles.

Carry out the Science Popularization of Vaccination to Advance the Initiative of "Healthy China 2030"

Vaccines rank to be one of the most effective methods for preventing infectious diseases. Since the introduction of the National Immunization Program in 1978, hepatitis B vaccine, BCG vaccine, polio vaccine, DPT vaccine and mumps vaccine have been successively included into Type I vaccines provided free of charge by the country to citizens, who shall be vaccinated in accordance with government regulations. However, EV71 vaccine against HFMD, pneumococcal vaccine, varicella vaccine and some other vaccines are not included in the National Immunization Program.

Despite the milestone development of National Immunization Program in China, and the continuous expansion in vaccine types and vaccination scale, the public still has blind spots in knowledge concerning vaccination. In order to enhance the public's acceptance of vaccines and lower the incidence of diseases by lifting the inoculation rate, in December 2021, Sinovac collaborated with the app People's Daily Health to launch the activity for vaccine science popularization themed by "Embrace longer protection at the cost of momentary pain".

By introducing the red "heartwarming special rail" in the mountain city Chongqing, the activity aimed to convince the masses that "vaccines may protect us from viruses in spite of the momentary prickling from inoculation". And the simultaneously issued short film Heart-wrenching, Heartwarming reproduced the heart-wrenching moments that numerous people have experienced or are experiencing with a view to calling on the public to pay attention to life and health and establish the awareness of disease prevention and control, and advance the realization of "Healthy China 2030".

The activity of "heartwarming special rail" received much attention upon issuance, the cumulative view counts of the short film of Heart-wrenching · Heartwarming reached 21.17 million, the accumulated view counts of the Weibo (China's Twitter-like platform) topic - "Heartwarming moments behind heart-wrenching words" are in excess of 300 million and the interactive discussions thereof are more than 100,000.



Co-build the Health Barrier for Influenza Prevention and Control through Health Science Popularization of Respiratory Infectious Diseases

To enhance the epidemic prevention and control during the high-incidence season of influenza, Sinovac collaborated with the medical platform DXY and launched health popularization of respiratory infectious diseases with a view to enhancing the masses' knowledge about preventing and controlling respiratory infectious diseases including influenza.

Oriented to the topic that "wearing long johns is inferior to getting influenza vaccines", this activity saw the presence of doctors popularizing the severity of influenza diseases and joint calls on influenza vaccination for the purpose of protecting oneself and high-risk groups around him/her.

Aside from donation to the public health field and health science popularization, Sinovac has made unceasing contributions to disaster relief assistance and poverty alleviation. In 2021, Sinovac went to Sichuan to facilitate the equitable distribution of vaccines and consolidate the achievements in poverty alleviation, and carried out the farmer assistance action in Xinjiang by organizing the procurement of walnuts planted by local peasants. Sinovac also donated relief materials valued nearly RMB8 million to Henan where was hit by severe floods at the first time.



Embrace the Future

2022 marks a new start of Sinovac's further development. In the coming year, Sinovac will continuously focus on its main business and increase its input for the purpose of promoting the innovative development of domestic vaccines and the biopharmaceutical industry and serving the health and well-being of mankind.

Increase Input and Focus on the Biopharmaceutical Field

Subject to the concept of "Protecting Lives, Delivering Health", Sinovac, in the future, will continuously increase its input in the biopharmaceutical industry. As planned, in the coming 5 years, Sinovac will invest RMB10 billion to support the fundamental research, innovative R&D and industrialization in the biopharmaceutical field, and to encourage the development of Chinese biopharmaceutical field. Aside from more investment in its own R&D, Sinovac plans to deepen its cooperation with multiple universities and scientific research institutions with a view to accelerating the pace of in-depth integration of industry-university-research-application. In 2022, Sinovac will provide free assistance to Shenyang Pharmaceutical University in the construction of Cell Test Central Lab, conclude an agreement with the Chinese University of Hong Kong for the co-building of BSL-3 Lab, and collaborate with the Institute of Biophysics of Chinese Academy of Sciences to build the "United Lab of Cutting-edge Technology and Novel Vaccines & Drugs" and establish the "Life Medicine Award of Sinovac". The foregoing measures will continuously reinforce Sinovac's hard power of science and technology, enhance the innovation capability of the Chinese pharmaceutical industry, and contribute to the realization of 'Healthy China".

Join the Global Anti-Epidemic Community and Ensure Vaccine Supply Boldly and Conscientiously

By the end of 2021, more than 2.5 billion doses of CoronaVac® had been supplied worldwide, and more than 2 billion doses had been vaccinated globally, remarkably contributing to the global cause of fighting the COVID-19 pandemic. In the coming year, Sinovac will unswervingly fulfill its commitment of "vaccine as global public product", enhance its fundamental research, and facilitate the realization of industrialization achievements, in a bid to make vaccines safe and accessible, ensure the vaccine supply on the global scale, bridge the "global immunization gap", and make Sinovac a Chinese brand that is trusted by Chinese people and the whole world in the biopharmaceutical field.

Pursue Sustainable Development Patterns to Perform Duties

In the coming year, Sinovac will continuously comply with the bottom line of compliance, improve the anti-corruption and integrity system, and ensure its integrity management. Directly by the goal of "peak carbon emissions and carbon neutrality", Sinovac will strive for the green and low-carbon development. Furthermore, the Company will unceasingly enhance industry cooperation and technical exchange, and cooperate with relevant parties to facilitate industry chain upgrading and benign industry development. In respect of employees, Sinovac will provide them with a healthy, diversified and heartwarming work environment, remain dedicated to cultivating and delivering talents required by the industry, and provide solid guarantee for employee development. In 2022, Sinovac will continuously focus on the public welfare establishments, promote social equity and community development, and contribute to the realization of rural revitalization and common prosperity.

In the coming 2022, Sinovac will seize the development opportunities, unlock innovation vitality, expand international cooperation, shoulder social responsibility, practice enterprise mission, and contribute to the health cause of China and even of all human beings.

2021 Key Performance Sheet

Dimension	Indicator	Numerical Value
Economy	Vaccine Supply (Dose 10^8)	25
	National/Provincial Key Scientific Research Projects	9
	Patent Licensing Received	13
	Marketing of New Products	3
	Participation in the Formulation of National Standards	11
	Newly-Received Clinical Approval	4
Environment	Total Input in Environmental Protection (RMB 10^4)	4,206
	Power Consumption (kWh)	114,700,527
	Gas Consumption (m^3)	4,173,664
	Amount of Recycled Waste (Ton)	258
	Annual Water Consumption (Ton)	2,149,216
	Frequency of Environmental Protection Training (Times)	26
	Number of Trainees of Environmental Protection Training (Person)	4,935
Society	Aggregate Amount of Charitable Donations (RMB 10^4)*	92,351
	Total Vaccine Donations (Dose 10^6)	＞300
	Proportion of Annual Compliance Suppliers	100%
	Quantity of Supplier Appraisal Completed	96
	Safety Training Input (RMB 10^4)	162.39
	Safety Production Input (RMB 10^4)	3,138.07
	Frequency of Safety Training (Times)	81
	Coverage Rate of Safety Training	100%
	Frequency of Safety Emergency Drills (Times)	39
	Major Safety Accidents (Accident)	0
	Number of Staff Suffering Occupational Diseases (Person)	0
	Coverage Rate of Check-ups and Health Archives	100%
	Frequency of Occupational Health Training (Times)	30
Society	Proportion of Female Employees	42%
	Proportion of Female Managers	48%
	Proportion of Minority Employees	9%
	Employment Rate of the Disabled	1%
	Signing Rate of Employment Contract	100%
	Coverage Rate of Social Insurance	100%
	Employee training coverage	100%
	Biosafety Incident	0
	Number of Trainees of Product Quality Safety Training (Person)	9,448
	Pharmacovigilance Training	18

*The aggregate amount of charitable donations does not include vaccine donations

Indicator Index (GRI)

Table of Contents		GRI Standard
About the Report		GRI-101, GRI-102
About Sinovac	Corporate Profile	GRI-102
	History	GRI-102
	Main Products	GRI-102, GRI-416
Social Responsibility Strategy and Management	Corporate Social Responsibility Strategy and Management	GRI-102, GRI-103
	Communication with Stakeholders	GRI-102, GRI-103
	Analysis on Substantive Issues	GRI-102, GRI-103
Contribution to the Realization of 2030 Sustainable Development Goals of the United Nations	SDGs Map of Sinovac	GRI-102, GRI-103
	Drive the "ANTI COVID-19 ACTION" to Fight against the COVID-19 Pandemic	GRI-102, GRI-103, GRI-203, GRI-415, GRI-416
	Benefit the World and Contribute to Fight against the COVID-19 Pandemic Worldwide through Sinovac's Vaccines	GRI-102, GRI-103, GRI-203, GRI-204, GRI-415
	Remain Dedicated to the R&D and Supply of Vaccines for 20 Years	GRI-102, GRI-103, GRI-203, GRI-416
Excellent Governance to Enhance Sustainable Development	Compliance and Risk Control	GRI-102, GRI-103
	Integrity Managemen	GRI-102, GRI-205, GRI-206
	Responsible Supply Chain	GRI-102, GRI-204, GRI-308, GRI-409, GRI-414
Continuous Innovation for Better Health	R&D and Innovation	GRI-102, GRI-203, GRI-416
	Vaccine Quality and Supply	GRI-102, GRI-203, GRI-416
	Customer Service	GRI-102, GRI-203, GRI-416, GRI-417, GRI-418
Communion and Co-construction Create Shared Value	Promote the Sound Development of the Industry	GRI102
	Proactively Carry out International Cooperation	GRI102
Green Development Build Beautiful Home	Environmental Management Framework	GRI103
	Make Aggressive Efforts for Energy Conservation and Emission Reduction	GRI103, GRI302
	Fully Carry Out Cleaner Production	GRI103, GRI307
	Water Resource Management	GRI103
	Green Logistics and Warehousing	GRI301, GRI302
Heartwarming Workplace Grow with Employees	Protection of Employees' Rights and Interests	GRI103, GRI401, GRI403
	Diversity of Employees and Equality of Opportunities	GRI405
	Occupational Health and Safety of Employees	GRI103, GRI403
	Employee Growth and Development	GRI404
	Care for Employees	GRI401
Benefit the Society Achieve Common Prosperity	Deliver Health and Wellbeing by Fulfilling Public Responsibility	GRI102, GRI203
	Safeguard the Public Health through Health Science Popularization	GRI102, GRI203
Embrace the Future		GRI102, GRI203
2021 Major Honors and Awards		
2021 Key Performance Sheet		GRI102, GRI201, GRI203, GRI302, GRI303, GRI305, GRI306, GRI403, GRI405
Indicator Index (GRI)		

为人类消除疾病提供疫苗

Supply Vaccines to Eliminate Human Diseases

SINOVAC科兴

Sinovac Biotech Ltd.
Add: No.39, SHANGDI West Road, Haidian District, Beijing, P.R.C.
Tel: +86-10-82890088
Website：www.sinovac.com
E-mail: sinovac@sinovac.com

This report is made of renewable environmental protection paper